Journal of Clinical Psychiatry

Subject Index to Volume 60: January 1999 Through December 1999

Academic Highlights
Role of norepinephrine in the treatment of depression. Sept 623–631
Adolescents
Methods of adolescent suicide prevention. Shaffer, Suppl 2, 70–74
Pharmacotherapy of depressive illness in adolescents: an open-label comparison of fluoxetine with imipramine-treated historical controls. Strober, Mar 164–169
Adrenoleukodystrophy
Late-onset adrenoleukodystrophy associated with long-standing psychiatric symptoms. Garside, July 460–468
Age
Effects of gender and age on plasma levels of clozapine and its metabolites: analyzed by critical statistics. Lane, Jan 36–40
Gender-related clinical differences in older patients with schizophrenia [CME]. Lindamer, Jan 61–67
Aggression
Aggressive behavior in patients with attention-deficit/hyperactivity disorder, conduct disorder, and pervasive developmental disorders. Weller, Suppl 15, 5–11
Brain imaging correlates. Krishnan, Suppl 15, 50–54
Clozapine reduces severe self-mutilation and aggression in psychotic patients with borderline personality disorder. Chengappa, July 477–484
Effects of clozapine on aggression and substance abuse in schizophrenic patients. Volavka, Suppl 12, 43–46
Evaluation and management of aggressive behavior in the elderly demented patient. Raskind, Suppl 15, 45–49
Introduction: phenomenology and treatment of aggression across psychiatric illnesses. Nemeroff, Suppl 15, 3–4
Managing aggressive behavior in patients with obsessive-compulsive disorder and borderline personality disorder. Hollander, Suppl 15, 38–44
Managing anger and aggression in patients with posttraumatic stress disorder. Yehuda, Suppl 15, 33–37
Primate models to understand human aggression. Kalin, Suppl 15, 29–32
Role of typical and atypical antipsychotic medication in the management of agitation and aggression. Buckley, Suppl 10, 52–60
Treatment of aggression in patients with bipolar disorder. Swann, Suppl 15, 25–28
Agitation
Management of psychosis and agitation in elderly patients: a primary care perspective. Bulow, Suppl 13, 22–25
Phenomenology and treatment of agitation. Schatzberg, Suppl 15, 17–20
Role of typical and atypical antipsychotic medication in the management of agitation and aggression. Buckley, Suppl 10, 52–60
Treatment of agitation in dementia. Tariot, Suppl 8, 11–20
Alcohol and Alcoholism
Case report of reduction in alcohol craving and protection against alcohol withdrawal by gabapentin [letter]. Chatterjee, Sept 617
Measurement of compliance with naltrexone in the treatment of alcohol dependence: clinical and research implications. Namkoong, July 449–453
Study of impulse-control disorders among alcohol-dependent patients. Lejoyeux, May 302–305
Algorithm, Medication
Mental health care from the public perspective: Texas Medication Algorithm Project. Shon, Suppl 3, 16–20
Alzheimer's Disease
Effects of metrifonate on the cognitive, behavioral, and functional performance of Alzheimer's disease patients. Raskind, May 318–325
Amenorrhea
Risperidone and associated amenorrhea: a report of 5 cases. Kim, May 315–317
Anetholtrithion
Anetholtrithion stabilizes body weight fluctuation caused by excessive water drinking in a patient with schizophrenia: a case report [letter]. Matsuo, Oct 706
Anger
Anger attacks: correlates and significance of an underrecognized symptom [CME]. Mammen, Sept 633–642
Anger attacks in patients with depression. Fava, Suppl 15, 21–24
Managing anger and aggression in patients with posttraumatic stress disorder. Yehuda, Suppl 15, 33–37
Anorexia Nervosa
Fertility and reproduction in women with anorexia nervosa: a controlled study [CME]. Bulik, Feb 130–135
Anticonvulsants
Anticonvulsant therapy and suicide risk in affective disorders. Goodwin, Suppl 2, 89–93
Antidepressants see also specific drugs
Adverse reactions of antidepressants in elderly patients. Pollock, Suppl 20, 4–8
Antidepressant effectiveness in severe depression and melancholia. Schatzberg, Suppl 4, 14–21
Antidepressant efficacy in HIV-seropositive outpatients with major depressive disorder: an open trial of nefazodone. Elliott, Apr 226–231
Antidepressants: the Blue-Chip psychotropic for the modern treatment of anxiety disorders [Brainstorms]. Stahl, June 356–357
Antidepressants and suicidal risk. Müller-Oerlinghausen, Suppl 2, 94–99
Antidepressant treatment of depression in HIV-seropositive women. Ferrando, Nov 741–746
Antidepressant treatment of the depressed patient with insomnia. Thase, Suppl 17, 28–31
Can long-term antidepressant use be depressogenic? [letter] El-Mallakh; Rothschild reply, Apr 263–264
Chromium potentiation of antidepressant pharmacotherapy for dysthymic disorder in 5 patients. McLeod, Apr 237–240
Depression in the medical setting: biopsychological interactions and treatment considerations. Evans DL, Suppl 4, 40–55
Do depressed subjects who have failed both fluoxetine and a tricyclic respond to the combination? Levitt, Sept 613–616
Effectiveness of antidepressants in elderly depressed outpatients: a prospective case series study. Mittmann, Oct 690–697
Efficacy of SSRIs and newer antidepressants in severe depression: comparison with TCAs. Hirschfeld, May 326–335
Introduction: assessing antidepressant efficacy. Evans DL, Suppl 4, 3
Introduction: defining remission in patients treated with antidepressants. Thase, Suppl 22, 3–6
Introduction. Goal of antidepressant therapy: response or remission and recovery? Rudolph, Suppl 6, 3–4
Major depression in 1998: are we providing optimal therapy? Angst, Suppl 6, 5–9
Management of sexual side effects of antidepressant therapy. Hirschfeld, Suppl 14, 27–30
Mechanism of action of antidepressant medications. Feighner, Suppl 4, 4–11
Models of antidepressant action. Berman, Suppl 14, 16–20
New developments in the treatment of depression. Montgomery, Suppl 14, 10–15
Overview of antidepressants currently used to treat anxiety disorders. Feighner, Suppl 22, 18–22
Patient's coping skills and environmental stress important to understanding recurrence during antidepressant maintenance [letter]. Hart, Aug 556
Pharmacokinetic considerations of antidepressant use in the elderly. DeVane, Suppl 20, 38–44
Pharmacology of antidepressants: selectivity or multiplicity? Westenberg, Suppl 17, 4–8
Redefining antidepressant efficacy toward long-term recovery. Thase, Suppl 6, 15–19
Relationship between antidepressant treatment and suicide [letter]. Rich; Praschak-Rieder reply, May 340
Strategies and tactics in the management of maintenance treatment for depressed patients. Rush, Suppl 14, 21–26
Summary: defining remission in patients treated with antidepressants. Thase, Suppl 22, 35–36
Tolerability and patient compliance. Roose, Suppl 17, 14–17
Treatment of major depression: is improvement enough? Ferrier, Suppl 6, 10–14

Journal of Clinical Psychiatry

Subject Index to Volume 60: January 1999 Through December 1999

Academic Highlights
Role of norepinephrine in the treatment of depression. Sept 623–631
Adolescents
Methods of adolescent suicide prevention. Shaffer, Suppl 2, 70–74
Pharmacotherapy of depressive illness in adolescents: an open-label comparison of fluoxetine with imipramine-treated historical controls. Strober, Mar 164–169
Adrenoleukodystrophy
Late-onset adrenoleukodystrophy associated with long-standing psychiatric symptoms. Garside, July 460–468
Age
Effects of gender and age on plasma levels of clozapine and its metabolites: analyzed by critical statistics. Lane, Jan 36–40
Gender-related clinical differences in older patients with schizophrenia [CME]. Lindamer, Jan 61–67
Aggression
Aggressive behavior in patients with attention-deficit/hyperactivity disorder, conduct disorder, and pervasive developmental disorders. Weller, Suppl 15, 5–11
Brain imaging correlates. Krishnan, Suppl 15, 50–54
Clozapine reduces severe self-mutilation and aggression in psychotic patients with borderline personality disorder. Chengappa, July 477–484
Effects of clozapine on aggression and substance abuse in schizophrenic patients. Volavka, Suppl 12, 43–46
Evaluation and management of aggressive behavior in the elderly demented patient. Raskind, Suppl 15, 45–49
Introduction: phenomenology and treatment of aggression across psychiatric illnesses. Nemeroff, Suppl 15, 3–4
Managing aggressive behavior in patients with obsessive-compulsive disorder and borderline personality disorder. Hollander, Suppl 15, 38–44
Managing anger and aggression in patients with posttraumatic stress disorder. Yehuda, Suppl 15, 33–37
Primate models to understand human aggression. Kalin, Suppl 15, 29–32
Role of typical and atypical antipsychotic medication in the management of agitation and aggression. Buckley, Suppl 10, 52–60
Treatment of aggression in patients with bipolar disorder. Swann, Suppl 15, 25–28
Agitation
Management of psychosis and agitation in elderly patients: a primary care perspective. Bulow, Suppl 13, 22–25
Phenomenology and treatment of agitation. Schatzberg, Suppl 15, 17–20
Role of typical and atypical antipsychotic medication in the management of agitation and aggression. Buckley, Suppl 10, 52–60
Treatment of agitation in dementia. Tariot, Suppl 8, 11–20
Alcohol and Alcoholism
Case report of reduction in alcohol craving and protection against alcohol withdrawal by gabapentin [letter]. Chatterjee, Sept 617
Measurement of compliance with naltrexone in the treatment of alcohol dependence: clinical and research implications. Namkoong, July 449–453
Study of impulse-control disorders among alcohol-dependent patients. Lejoyeux, May 302–305
Algorithm, Medication
Mental health care from the public perspective: Texas Medication Algorithm Project. Shon, Suppl 3, 16–20
Alzheimer's Disease
Effects of metrifonate on the cognitive, behavioral, and functional performance of Alzheimer's disease patients. Raskind, May 318–325
Amenorrhea
Risperidone and associated amenorrhea: a report of 5 cases. Kim, May 315–317
Anetholtrithion
Anetholtrithion stabilizes body weight fluctuation caused by excessive water drinking in a patient with schizophrenia: a case report [letter]. Matsuo, Oct 706
Anger
Anger attacks: correlates and significance of an underrecognized symptom [CME]. Mammen, Sept 633–642
Anger attacks in patients with depression. Fava, Suppl 15, 21–24
Managing anger and aggression in patients with posttraumatic stress disorder. Yehuda, Suppl 15, 33–37
Anorexia Nervosa
Fertility and reproduction in women with anorexia nervosa: a controlled study [CME]. Bulik, Feb 130–135
Anticonvulsants
Anticonvulsant therapy and suicide risk in affective disorders. Goodwin, Suppl 2, 89–93
Antidepressants see also specific drugs
Adverse reactions of antidepressants in elderly patients. Pollock, Suppl 20, 4–8
Antidepressant effectiveness in severe depression and melancholia. Schatzberg, Suppl 4, 14–21
Antidepressant efficacy in HIV-seropositive outpatients with major depressive disorder: an open trial of nefazodone. Elliott, Apr 226–231
Antidepressants: the Blue-Chip psychotropic for the modern treatment of anxiety disorders [Brainstorms]. Stahl, June 356–357
Antidepressants and suicidal risk. Müller-Oerlinghausen, Suppl 2, 94–99
Antidepressant treatment of depression in HIV-seropositive women. Ferrando, Nov 741–746
Antidepressant treatment of the depressed patient with insomnia. Thase, Suppl 17, 28–31
Can long-term antidepressant use be depressogenic? [letter] El-Mallakh; Rothschild reply, Apr 263–264
Chromium potentiation of antidepressant pharmacotherapy for dysthymic disorder in 5 patients. McLeod, Apr 237–240
Depression in the medical setting: biopsychological interactions and treatment considerations. Evans DL, Suppl 4, 40–55
Do depressed subjects who have failed both fluoxetine and a tricyclic respond to the combination? Levitt, Sept 613–616
Effectiveness of antidepressants in elderly depressed outpatients: a prospective case series study. Mittmann, Oct 690–697
Efficacy of SSRIs and newer antidepressants in severe depression: comparison with TCAs. Hirschfeld, May 326–335
Introduction: assessing antidepressant efficacy. Evans DL, Suppl 4, 3
Introduction: defining remission in patients treated with antidepressants. Thase, Suppl 22, 3–6
Introduction. Goal of antidepressant therapy: response or remission and recovery? Rudolph, Suppl 6, 3–4
Major depression in 1998: are we providing optimal therapy? Angst, Suppl 6, 5–9
Management of sexual side effects of antidepressant therapy. Hirschfeld, Suppl 14, 27–30
Mechanism of action of antidepressant medications. Feighner, Suppl 4, 4–11
Models of antidepressant action. Berman, Suppl 14, 16–20
New developments in the treatment of depression. Montgomery, Suppl 14, 10–15
Overview of antidepressants currently used to treat anxiety disorders. Feighner, Suppl 22, 18–22
Patient's coping skills and environmental stress important to understanding recurrence during antidepressant maintenance [letter]. Hart, Aug 556
Pharmacokinetic considerations of antidepressant use in the elderly. DeVane, Suppl 20, 38–44
Pharmacology of antidepressants: selectivity or multiplicity? Westenberg, Suppl 17, 4–8
Redefining antidepressant efficacy toward long-term recovery. Thase, Suppl 6, 15–19
Relationship between antidepressant treatment and suicide [letter]. Rich; Praschak-Rieder reply, May 340
Strategies and tactics in the management of maintenance treatment for depressed patients. Rush, Suppl 14, 21–26
Summary: defining remission in patients treated with antidepressants. Thase, Suppl 22, 35–36
Tolerability and patient compliance. Roose, Suppl 17, 14–17
Treatment of major depression: is improvement enough? Ferrier, Suppl 6, 10–14

Treatment options for refractory depression. Shelton, Suppl 4, 57–61
Why settle for silver, when you can go for gold? response vs. recovery as the goal of antidepressant therapy. Stahl, Apr 213–214
Antipsychotics see also specific drugs
Adding other antipsychotics to clozapine [letter]. Leon, Oct 710
Adherence to antipsychotic medications. Perkins, Suppl 21, 25–30
Antipsychotic polypharmacy, part 1: therapeutic option or dirty little secret? [BRAINSTORMS] Stahl, July 425–426
Antipsychotics from theory to practice: integrating clinical and basic data. Tandon, Suppl 8, 21–28
Clinical heterogeneity between atypical antipsychotics in the treatment of schizophrenia: a case report. Taboada, Suppl 23, 23–24
Clozapine: a comparison with other novel antipsychotics. Fleischhacker, Suppl 12, 30–34
Cognitive dysfunction in schizophrenia and its importance to outcome: the place of atypical antipsychotics in treatment. Velligan, Suppl 23, 25–26
Continuing problem of extrapyramidal symptoms: strategies for avoidance and effective treatment. Gerlach, Suppl 23, 20
D_2 and 5-HT_2 receptor effects of antipsychotics: bridging basic and clinical findings using PET. Remington, Suppl 10, 15–19
Deliberate self-poisoning following fluvoxamine-neuroleptics combination [letter]. Chong, Dec 869
Different influences of classical antipsychotics and clozapine on glucose-insulin homeostasis in patients with schizophrenia or related psychoses. Melkersson, Nov 783–791
Do antipsychotic medications decrease the risk of suicide in patients with schizophrenia? Palmer, Suppl 2, 100–103
Effectiveness of combining atypical antipsychotics and psychosocial rehabilitation in a community mental health center setting. Noordsy, Suppl 19, 47–53
Efficacy, safety, and tolerability of antipsychotics in the elderly. Maixner, Suppl 8, 29–41
Introduction. Antipsychotic agents: clinical, economic, and legal considerations in the treatment of psychosis. Lehman, Suppl 19, 3–4
Introduction: newer drugs for older patients. Jeste, Suppl 13, 3–4
Introduction: what makes an antipsychotic atypical? Stahl, Suppl 10, 3–4
Management of acute mania. Tohen, Suppl 5, 31–34
Methods of cost-effectiveness analysis in the evaluation of new antipsychotics: implications for schizophrenia treatment. Neumann, Suppl 3, 9–14
New antipsychotic agents: emerging clinical profiles. Buckley, Suppl 1, 12–17
New vs. old antipsychotics: the Texas experience. Reid, Suppl 1, 23–25
Novel antipsychotics: comparison of weight gain liabilities. Wirshing, June 358–363
Overview of the treatment of schizoaffective disorder. McElroy, Suppl 5, 16–21
Partial response to antipsychotic treatment: the patient with enduring symptoms. Emsley, Suppl 23, 10–11
Pharmacologic and pharmacokinetic considerations in choosing an antipsychotic. Ereshefsky, Suppl 10, 20–30
Psychopharmacology of atypical antipsychotics and clinical outcomes in elderly patients. Kumar, Suppl 13, 5–9
Receptor pharmacology of neuroleptics: relation to clinical effects. Richelson, Suppl 10, 5–14
Relative weight gain among antipsychotics [letter]. Masand; Stahl reply, Oct 706–707
Role of typical and atypical antipsychotic medication in the management of agitation and aggression. Buckley, Suppl 10, 52–60
Selecting an atypical antipsychotic by combining clinical experience with guidelines from clinical trials. Stahl, Suppl 10, 31–41
Some adverse effects of antipsychotics: prevention and treatment. Lader, Suppl 12, 18–21
Suicide victims with schizophrenia in different treatment phases and adequacy of antipsychotic medication [CME]. Heilä, Mar 200–208
Treatment of Schizophrenia 1999 [Expert Consensus Guideline Series]. McEvoy, Suppl 11, 1–80
Use patterns for antipsychotic medications in Medicaid patients with schizophrenia. McCombs, Suppl 19, 5–13
Weight gain and antipsychotic medications [letter]. Aquila; Masand reply, May 336–337
Weight gain associated with antipsychotic drugs. Ganguli, Suppl 21, 20–24
Anxiety see also Generalized Anxiety Disorder; Social Anxiety Disorder
Care of depressed patients with anxiety symptoms. Nutt, Suppl 17, 23–27
Clinical guidelines for establishing remission in patients with depression and anxiety. Ballenger, Suppl 22, 29–34
Depressive and anxiety symptoms in patients with schizophrenia and schizophreniform disorder. Emsley, Nov 747–751
Economic burden of anxiety disorders in the 1990s. Greenberg PE, July 427–435
Efficacy of fluvoxamine in the treatment of major depression with comorbid anxiety disorders. Sonawalla, Sept 580–583
Efficacy, safety, and tolerability of venlafaxine extended release and buspirone in outpatients with generalized anxiety disorder. Davidson, Aug 528–535
Functional anatomy, neurochemistry, and pharmacology of anxiety. Ninan, Suppl 22, 12–17
Gender differences in the epidemiology and treatment of anxiety disorders. Pigott, Suppl 18, 4–15
Introduction: new treatments for anxiety disorders: clinical approaches for successful outcomes. Sheehan, Suppl 18, 3
Management of anxious depression in primary care. Goldberg D, Suppl 7, 39–42
Once-daily venlafaxine extended release (XR) compared with fluoxetine in outpatients with depression and anxiety. Silverstone, Jan 22–28
Overview of antidepressants currently used to treat anxiety disorders. Feighner, Suppl 22, 18–22
Patient with comorbid depression and anxiety: the unmet need. Bakish, Suppl 6, 20–24
Relationship between borderline personality disorder and axis I diagnosis in severity of depression and anxiety. Comtois, Nov 752–758
Attention-Deficit/Hyperactivity Disorder
Aggressive behavior in patients with attention-deficit/hyperactivity disorder, conduct disorder, and pervasive developmental disorders. Weller, Suppl 15, 5–11
Augmentation see Drug Therapy, Combination
Bipolar Disorder
Antidepressant discontinuation–related mania: critical prospective observation and theoretical implications in bipolar disorder [CME]. Goldstein, Aug 563–567
Bipolar II disorder vs. premenstrual dysphoric disorder [letter]. Macmillan, June 409–410
Clinical experience with gabapentin in patients with bipolar or schizoaffective disorder: results of an open-label study. Cabras, Apr 245–248
Clinical practice guidelines for bipolar disorder from the Department of Veterans Affairs. Bauer, Jan 9–21
Double-blind, placebo-controlled study of lamotrigine monotherapy in outpatients with bipolar I depression. Calabrese, Feb 79–88
Effects of chronic lithium treatment on the peripheral nervous system. Faravelli, May 306–310
Effects of lithium treatment and its discontinuation on suicidal behavior in bipolar manic-depressive disorders. Baldessarini, Suppl 2, 77–84
History of substance abuse complicates remission from acute mania in bipolar disorder. Goldberg JF, Nov 733–740
Isotretinoin treatment of a woman with bipolar disorder [letter]. Wisner, June 407–408
Mood stabilizers and the evolution of maintenance study designs in bipolar I disorder. Calabrese, Suppl 5, 5–13
New vs. old antipsychotics: the Texas experience. Reid, Suppl 1, 23–25
Rapid fade of antidepressant effect of nefazodone in bipolar depression [letter]. El-Mallakh, Aug 559
Risk of suicide in patients with bipolar disorders. Simpson SG, Suppl 2, 53–56
Safety and tolerability of oral loading divalproex sodium in acutely manic bipolar patients. Hirschfeld, Dec 815–818
Treatment of aggression in patients with bipolar disorder. Swann, Suppl 15, 25–28
Body Dysmorphic Disorder
Comorbid social anxiety and body dysmorphic disorder: managing the complicated patient. Hollander, Suppl 9, 27–31
Body Mass Index
Distribution of body mass index among individuals with and without schizophrenia. Allison, Apr 215–220
Books Reviewed
Alarcón RD, Foulks EF, Vakkur M (eds): *Personality Disorder and Culture: Clinical and Conceptual Interactions.* Ruiz, Mar 197
Barkley RA, Murphy KR (eds): *Attention-Deficit Hyperactivity Disorder: Clinical Workbook, 2nd ed.* Fuchs, Feb 127–128
Bear MF, Connors BW, Paradisio MA: *Neuroscience: Exploring the Brain.* Deutch, Jan 59
Bernstein BE, Hartsell TL: *Portable Lawyer for Mental Health Professionals: An A–Z Guide to Protecting Your Clients, Your Practice, and Yourself.* Moore, Apr 265
Bremner JD, Marmar CR (eds): *Trauma, Memory, and Dissociation.* Miller, Sept 621–622
Briley M, Montgomery S (eds): *Antidepressant Therapy at the Dawn of the Third Millennium.* Shelton, Oct 711–712
Brown TM, Stoudemire A: *Psychiatric Side Effects of Prescription and Over-the-Counter Medications: Recognition and Management.* Solomon, Jan 58–59
Campbell TW: *Smoke and Mirrors: The Devastat-*

ing Effect of False Sexual Abuse Claims. Nurcombe, Dec 871–872
Carvey PM: *Drug Action in the Central Nervous System.* Ciraulo, Dec 871
Clark DM, Fairburn CG (eds): *Science and the Practice of Cognitive Behaviour Therapy.* Shelton, May 343
Coffey E (ed): *Textbook of Pediatric Neuropsychiatry.* Bernet, July 490
Committee on Child Psychiatry for GAP: *In the Long Run . . . Longitudinal Studies of Psychopathology in Children (GAP Report No. 143).* Fuchs, Aug 560
Frances RJ, Miller SI (eds): *Clinical Textbook of Addictive Disorders, 2nd ed.* Martin, Dec 872
Gabbard GO, Gabbard K: *Psychiatry and the Cinema, 2nd ed.* Fitzgerald RG, Oct 712
Goldberg JF, Harrow MH: *Bipolar Disorders: Clinical Course and Outcome.* Freed, Nov 797
Hartmann E: *Dreams and Nightmares: New Theory on the Origin and Meaning of Dreams.* Gillin, Apr 265–266
Ingram RE, Miranda J, Segal ZV: *Cognitive Vulnerability to Depression.* Miller, Mar 197–198
Katschnig H, Freeman H, Sartorius N (eds): *Quality of Life in Mental Disorders.* Silverman, July 489–490
Lam R (ed): *Seasonal Affective Disorder and Beyond: Light Treatment for SAD and Non-SAD Conditions.* Risby, June 411
Lazarus JA, Sharfstein SS (eds): *New Roles for Psychiatrists in Organized Systems of Care.* Racy, Jan 58
Markowitz JC: *Interpersonal Psychotherapy for Dysthymic Disorder.* Vakoch, Sept 621
Marlatt GA (ed): *Harm Reduction: Pragmatic Strategies for Managing High-Risk Behaviors.* Hubbard, June 412
Mash EJ, Barkley RA (eds): *Treatment of Childhood Disorders, 2nd ed.* Maloney, June 411–412
McCance-Katz, Kosten TR (eds): *New Treatments for Chemical Addictions (Review of Psychiatry Series, Vol. 17).* Weinstein, Aug 561
Moore BE, Fine BD (eds): *Psychoanalysis: Major Concepts.* Nash, Feb 126–127
Murray R, Hill P, McGuffin P (eds): *Essentials of Postgraduate Psychiatry, 3rd ed.* Freeman AM, May 342–343
Nasar S: *Beautiful Mind: A Biography of John Forbes Nash, Jr.* Meltzer HY, Apr 266
Pincus HA, Lieberman JA, Ferris S (eds): *Ethics in Psychiatric Research: A Resource Manual for Human Subjects Protection.* Salomon, Aug 560–561
Pruitt DB (ed): *Your Child—What Every Parent Needs to Know: What's Normal, What's Not, and When to Seek Help.* Quintero, July 489
Rosenbaum JF, Pollack MH (eds): *Panic Disorder and Its Treatment.* Noyes, May 343–344
Salzman C (ed): *Clinical Geriatric Psychopharmacology, 3rd ed.* Thienhaus, Oct 711
Shorter E: *History of Psychiatry: From the Era of the Asylum to the Age of Prozac.* Cahn, Feb 127
Silver LB: *Attention-Deficit/Hyperactivity Disorder: A Clinical Guide to Diagnosis and Treatment for Health and Mental Health Professionals, 2nd ed.* Petti, Dec 872
Stern TA, Herman JB, Slavin PL (eds): *MGH Guide to Psychiatry in Primary Care.* Dieperink, Feb 128
Stotland NL: *Abortion Facts and Feelings: A Handbook for Women and the People Who Care About Them.* Andrade NN, Sept 622
Yehuda R (ed): *Psychological Trauma (Review of Psychiatry Series, Vol. 17).* Farmer, Oct 712

Borderline Personality Disorder
Clozapine reduces severe self-mutilation and aggression in psychotic patients with borderline personality disorder. Chengappa, July 477–484
Managing aggressive behavior in patients with obsessive-compulsive disorder and borderline personality disorder. Hollander, Suppl 15, 38–44
Naltrexone in the treatment of dissociative symptoms in patients with borderline personality disorder: an open-label trial. Schmahl, Sept 598–603
Relationship between borderline personality disorder and axis I diagnosis in severity of depression and anxiety. Comtois, Nov 752–758

Brain
Brain imaging correlates. Krishnan, Suppl 15, 50–54
Expression of the myristoylated alanine-rich C kinase substrate (MARCKS) and MARCKS-related protein (MRP) in the prefrontal cortex and hippocampus of suicide victims. McNamara, Suppl 2, 21–26

Brainstorms
Antidepressants: the Blue-Chip psychotropic for the modern treatment of anxiety disorders. Stahl, June 356–357
Antipsychotic polypharmacy, part 1: therapeutic option or dirty little secret? Stahl, July 425–426
Antipsychotic polypharmacy, part 2: tips on use and misuse. Stahl, Aug 506–507
Mergers and acquisitions among psychotropics: antidepressant takeover of anxiety may now be complete. Stahl, May 282–283
Molecular neurobiology for practicing psychiatrists, part 1: overview of gene activation by neurotransmitters. Stahl, Sept 572–573
Molecular neurobiology for practicing psychiatrists, part 2: how neurotransmitters activate second messenger systems. Stahl, Oct 647–648
Molecular neurobiology for practicing psychiatrists, part 3: how second messengers "turn on" genes by activating protein kinases and transcription factors. Stahl, Nov 731–732
Molecular neurobiology for practicing psychiatrists, part 4: transferring the message of chemical neurotransmission from presynaptic neurotransmitter to postsynaptic gene expression. Stahl, Dec 813–814
Peptides and psychiatry, part 1: how synthesis of neuropeptides differs from classical neurotransmitter synthesis. Stahl, Jan 5–6
Peptides and psychiatry, part 2: substance P and the neurokinins: novel peptide neurotransmitters in psychopharmacology. Stahl, Feb 77–78
Peptides and psychiatry, part 3: substance P and serendipity: novel psychotropics are a possibility. Stahl, Mar 140–141
Why settle for silver, when you can go for gold? Response vs. recovery as the goal of antidepressant therapy. Stahl, Apr 213–214

Breast Milk
Excretion of paroxetine into breast milk. Öhman, Aug 519–523

Bruxism
Buspirone as an antidote to SSRI-induced bruxism in 4 cases. Bostwick, Dec 857–860

Bupropion
Bupropion clarification [letter]. Kent, Mar 196
Development of depression during placebo-controlled trials of bupropion for smoking cessation: case reports. Patten, July 436–441
Ileus as a possible result of bupropion in an elderly woman [letter]. Kales, May 337

Buspirone
Buspirone as an antidote to SSRI-induced bruxism in 4 cases. Bostwick, Dec 857–860
Efficacy, safety, and tolerability of venlafaxine extended release and buspirone in outpatients with generalized anxiety disorder. Davidson, Aug 528–535

Cannabis
Effects of cannabis use on cognitive functions and driving ability. Kurzthaler, June 395–399

Capitation
Capitation [letter]. Sheeley; Glazer reply, Jan 54–55

Carbamazepine
Withdrawal from controlled carbamazepine therapy followed by further carbamazepine treatment in patients with dementia. Tariot, Oct 684–689

Carbon Dioxide
Sensitivity to 35% carbon dioxide in patients with generalized anxiety disorder. Perna, June 379–384

Chlorpromazine
Efficacy and safety of clozapine versus chlorpromazine in geriatric schizophrenia. Howanitz, Jan 41–44

Chorea
Chorea and tardive dyskinesia in a patient on risperidone [letter]. Carroll, July 485–487

Chromium
Chromium potentiation of antidepressant pharmacotherapy for dysthymic disorder in 5 patients. McLeod, Apr 237–240

Citalopram
Multicenter, placebo-controlled, fixed-dose study of citalopram in moderate-to-severe depression. Feighner, Dec 824–830
Two-year maintenance treatment with citalopram, 20 mg, in unipolar subjects with high recurrence rate. Franchini, Dec 861–865

Clinical Trials
How should efficacy be evaluated in randomized clinical trials of treatments for depression? Thase, Suppl 4, 23–31
Mood stabilizers and the evolution of maintenance study designs in bipolar I disorder. Calabrese, Suppl 5, 5–13
Selecting an atypical antipsychotic by combining clinical experience with guidelines from clinical trials. Stahl, Suppl 10, 31–41

Clomipramine
Paroxetine, clomipramine, and cognitive therapy in the treatment of panic disorder. Bakker, Dec 831–838

Clonazepam
Efficacy, safety, and gradual discontinuation of clonazepam in panic disorder: a placebo-controlled, multicenter study using optimized dosages. Moroz, Sept 604–612

Clozapine
Adding other antipsychotics to clozapine [letter]. de Leon, Oct 710
Clozapine: a comparison with other novel antipsychotics. Fleischhacker, Suppl 12, 30–34
Clozapine: the commitment to patient safety. Alphs, Suppl 12, 39–42
Clozapine and obsessions in patients with recent-onset schizophrenia and other psychotic disorders. de Haan, June 364–365
Clozapine for refractory schizophrenia: the Illinois experience. Buckman, Suppl 1, 18–22

Clozapine reduces severe self-mutilation and aggression in psychotic patients with borderline personality disorder. Chengappa, July 477–484
Clozapine versus risperidone in treatment-refractory schizophrenia: possible impact of dosing strategies [letter]. Lane, July 487–488
Different influences of classical antipsychotics and clozapine on glucose-insulin homeostasis in patients with schizophrenia or related psychoses. Melkersson, Nov 783–791
Effects of clozapine on aggression and substance abuse in schizophrenic patients. Volavka, Suppl 12, 43–46
Effects of clozapine on cognitive functioning in schizophrenia. McGurk, Suppl 12, 24–29
Effects of gender and age on plasma levels of clozapine and its metabolites: analyzed by critical statistics. Lane, Jan 36–40
Efficacy and safety of clozapine versus chlorpromazine in geriatric schizophrenia. Howanitz, Jan 41–44
Emergence of social phobia during clozapine treatment and its response to fluoxetine augmentation. Pallanti, Dec 819–823
Historical perspective of clozapine. Hippius, Suppl 12, 22–23
Olanzapine treatment after clozapine-induced granulocytopenia in 3 patients. Swartz, Feb 119–121
Optimizing clozapine treatment. Naber, Suppl 12, 35–38
Pharmacoeconomic evaluation of treatments for refractory schizophrenia: clozapine-related studies. Revicki, Suppl 1, 7–11
Seizures after discontinuation of low-dose lorazepam from originally seizure-free clozapine regimen: combined effects? [letter] Lane, June 408–409
Suicide and schizophrenia: clozapine and the InterSePT study. Meltzer HY, Suppl 12, 47–50
Transient syncope and ECG-changes associated with the concurrent administration of clozapine and diazepam [letter]. Tupala, Sept 619–620

Cognition

Associations between cognitive impairment and tardive dyskinesia: another perspective. Dodge, Suppl 13, 17–21
Cognitive dysfunction in schizophrenia and its importance to outcome: the place of atypical antipsychotics in treatment. Velligan, Suppl 23, 25–26
Cognitive effects of paroxetine in older depressed patients. Nebes, Suppl 20, 26–29
Cognitive functioning in late-life schizophrenia: its importance and implications for overall outcome. Harvey, Suppl 13, 10–16
Effects of cannabis use on cognitive functions and driving ability. Kurzthaler, June 395–399
Effects of clozapine on cognitive functioning in schizophrenia. McGurk, Suppl 12, 24–29
Quetiapine and cognitive improvement in a patient with schizophrenia. Stip, Suppl 23, 27–28

Cognitive-Behavioral Therapy

Cognitive-behavioral therapy as an adjunct to serotonin reuptake inhibitors in obsessive-compulsive disorder: an open trial. Simpson HB, Sept 584–590
Cognitive-behavioral therapy for social anxiety disorder: model, methods, and outcome. Otto, Suppl 9, 14–19
Paroxetine, clomipramine, and cognitive therapy in the treatment of panic disorder. Bakker, Dec 831–838

Comorbidity

Comorbidity in primary care: presentation and consequences. Wittchen, Suppl 7, 29–36

Compliance

Tolerability and patient compliance. Roose, Suppl 17, 14–17

Computers

Clinical features, psychiatric comorbidity, and health-related quality of life in persons reporting compulsive computer use behavior. Black, Dec 839–844
Home self-assessment and self-treatment of obsessive-compulsive disorder using a manual and a computer-conducted telephone interview: replication of a U.K.-U.S. study. Bachofen, Aug 545–549

Conduct Disorder

Aggressive behavior in patients with attention-deficit/hyperactivity disorder, conduct disorder, and pervasive developmental disorders. Weller, Suppl 15, 5–11

Consensus Statements

Consensus discussion: clinical and economic issues of treatment-resistant schizophrenia. Suppl 1, 28–30
Consensus statement on the primary care management of depression from the International Consensus Group on Depression and Anxiety. Ballenger, Suppl 7, 54–61
Summary and conclusions: effects of medical interventions on suicidal behavior. Baldessarini, Suppl 2, 117–122
Texas Medication Algorithm Project: report of the Texas Consensus Conference Panel on Medication Treatment of Major Depressive Disorder. Crismon, Mar 142–156
Treatment of Posttraumatic Stress Disorder [Expert Consensus Guideline Series]. Foa (ed), Suppl 16, 1–76
Treatment of Schizophrenia 1999 [Expert Consensus Guideline Series]. McEvoy (ed), Suppl 11, 1–80

Continuing Medical Education (CME)

Advances in the Treatment of Psychosis in the Elderly, Suppl 8, 1–60
Anger attacks: correlates and significance of an underrecognized symptom. Mammen, Sept 633–642
Antidepressant discontinuation–related mania: critical prospective observation and theoretical implications in bipolar disorder. Goldstein, Aug 563–567
Antipsychotic Agents: Clinical, Economic, and Legal Considerations in the Treatment of Psychosis, Suppl 19, 1–70
Assessing Antidepressant Efficacy: A Reexamination, Suppl 4, 1–66
Bright light therapy: side effects and benefits across the symptom spectrum. Terman, Nov 799–808
Critical overview: adverse cutaneous reactions to psychotropic medications. Kimyai-Asadi, Oct 714–725
Fertility and reproduction in women with anorexia nervosa: a controlled study. Bulik, Feb 130–135
Gender-related clinical differences in older patients with schizophrenia. Lindamer, Jan 61–67
Night terrors, sleepwalking, and confusional arousals in the general population: their frequency and relationship to other sleep and mental disorders. Ohayon, Apr 268–276
Panic disorder in the primary care setting: comorbidity, disability, service utilization, and treatment. Roy-Byrne, July 492–499
Patterns of remission and relapse in obsessive-compulsive disorder: a 2-year prospective study. Eisen, May 346–351
Phenomenology and Treatment of Aggression Across Psychiatric Illnesses, Suppl 15, 1–58
Psychiatric features of 36 men convicted of sexual offenses. McElroy, June 414–420
Schizoaffective disorder: a form of schizophrenia or affective disorder? [CME] Evans JD, Dec 874–882
Suicide victims with schizophrenia in different treatment phases and adequacy of antipsychotic medication. Heilä, Mar 200–208
Use of Mood Stabilizers for Treating Psychiatric Disorders, Suppl 5, 1–52
Use of Newer Antipsychotic Medications in the Elderly, Suppl 13, 1–28

Corrections

Clinical practice guidelines for bipolar disorder from the Department of Veterans Affairs. Bauer, Jan 9–21; Correction, May 341
Efficacy and safety of clozapine versus chlorpromazine in geriatric schizophrenia. Howanitz, Jan 41–44; Correction, May 341
Incidence of sexual dysfunction in healthy volunteers on fluvoxamine therapy. Nafziger, Mar 187–190; Correction, May 341

Costs of Medical Care

Annual health outcomes and treatment costs for schizophrenia populations. Mauskopf, Suppl 19, 14–22
Changes in perceived health and functioning as a cost-effectiveness measure for olanzapine versus haloperidol treatment of schizophrenia. Tunis, Suppl 19, 38–46
Cost of treating mental illness from a managed care perspective. Docherty, Suppl 3, 49–52
Cost-utility analysis in schizophrenia. Awad, Suppl 3, 22–26
Economic burden of anxiety disorders in the 1990s. Greenberg PE, July 427–435
Economic impact of schizophrenia. Rice, Suppl 1, 4–6
Introduction: pharmacoeconomics of treatment-resistant schizophrenia. Hanson, Suppl 1, 3
Methods of cost-effectiveness analysis in the evaluation of new antipsychotics: implications for schizophrenia treatment. Neumann, Suppl 3, 9–14
Panel on cost-effectiveness in health and medicine recommendations: identifying costs. Manning, Suppl 3, 54–56
Perspective and the measurement of costs and benefits for cost-effectiveness analysis in schizophrenia. Meltzer D, Suppl 3, 32–35
Pharmacoeconomic evaluation of treatments for refractory schizophrenia: clozapine-related studies. Revicki, Suppl 1, 7–11
Pharmacoeconomics of schizophrenia in the 21st century. Hanson, Suppl 1, 26–27
What about the patient? Weisburd, Suppl 3, 38–41

Cutaneous Reactions

Critical overview: adverse cutaneous reactions to psychotropic medications. Kimyai-Asadi, Oct 714–725

Cytochrome P450

Pilot study on risperidone metabolism: the role of cytochromes P450 2D6 and 3A. Bork, July 469–476

Delusions

Persecutory delusions in dementia. Hwang, Aug 550–553

Dementia
Comparison of risperidone and placebo for psychosis and behavioral disturbances associated with dementia: a randomized, double-blind trial. Katz, Feb 107–115
Evaluation and management of aggressive behavior in the elderly demented patient. Raskind, Suppl 15, 45–49
Metrifonate: update on a new antidementia agent. Ringman, Nov 776–782
Persecutory delusions in dementia. Hwang, Aug 550–553
Pharmacologic management of psychosis in dementia. Schneider, Suppl 8, 54–60
Treatment of agitation in dementia. Tariot, Suppl 8, 11–20
Withdrawal from controlled carbamazepine therapy followed by further carbamazepine treatment in patients with dementia. Tariot, Oct 684–689
Department of Veterans Affairs
Clinical practice guidelines for bipolar disorder from the Department of Veterans Affairs. Bauer, Jan 9–21
Depression
Anger attacks in patients with depression. Fava, Suppl 15, 21–24
Antidepressant effectiveness in severe depression and melancholia. Schatzberg, Suppl 4, 14–21
Antidepressant efficacy in HIV-seropositive outpatients with major depressive disorder: open trial of nefazodone. Elliott, Apr 226–231
Antidepressant treatment of depression in HIV-seropositive women. Ferrando, Nov 741–746
Best clinical practice: guidelines for managing major depression in primary medical care. Schulberg, Suppl 7, 19–26
Can long-term antidepressant use be depressogenic? [letter] El-Mallakh; Rothschild reply, Apr 263–264
Care of depressed patients with anxiety symptoms. Nutt, Suppl 17, 23–27
Care of the sexually active depressed patient. Hirschfeld, Suppl 17, 32–35
Clinical guidelines for establishing remission in patients with depression and anxiety. Ballenger, Suppl 22, 29–34
Comparing the efficacy and safety of fluoxetine and venlafaxine in outpatient depression [letter]. Michelson; Costa e Silva reply, May 338–340
Consensus statement on the primary care management of depression from the International Consensus Group on Depression and Anxiety. Ballenger, Suppl 7, 54–61
Continuation and maintenance pharmacotherapy in geriatric depression: an open-trial comparison of paroxetine and nortriptyline in patients older than 70 years. Walters, Suppl 20, 21–25
Depression in the community: physician and patient perspective. Tylee, Suppl 7, 12–16
Depression in the medical setting: biopsychological interactions and treatment considerations. Evans DL, Suppl 4, 40–55
Depression screening as an intervention against suicide. Jacobs, Suppl 2, 42–45
Depressive and anxiety symptoms in patients with schizophrenia and schizophreniform disorder. Emsley, Nov 747–751
Development of depression during placebo-controlled trials of bupropion for smoking cessation: case reports. Patten, July 436–441
Double-blind randomized comparison of nortriptyline and paroxetine in the treatment of late-life depression: 6-week outcome. Mulsant, Suppl 20, 16–20
Effects of venlafaxine on social activity level in depressed outpatients. Lenderking, Mar 157–163
Efficacy of fluvoxamine in the treatment of major depression with comorbid anxiety disorders. Sonawalla, Sept 580–583
Efficacy of SSRIs and newer antidepressants in severe depression: comparison with TCAs. Hirschfeld, May 326–335
Epidemiology and diagnosis of depression in late life. Mulsant, Suppl 20, 9–15
Evolution of remission as the new standard in the treatment of depression. Nierenberg, Suppl 22, 7–11
Genetics of suicide in depression. Roy, Suppl 2, 12–17
How should efficacy be evaluated in randomized clinical trials of treatments for depression? Thase, Suppl 4, 23–31
Introduction: focus on primary care management of depression. Ballenger, Suppl 7, 3
Introduction. Goal of antidepressant therapy: response or remission and recovery? Rudolph, Suppl 6, 3–4
Introduction: treatment of depression in long-term care patients. Pollock, Suppl 20, 3
Legal and ethical considerations in the treatment of psychosis. Fitzgerald WL Jr, Suppl 19, 59–65
Long-term nature of depression. Thase, Suppl 14, 3–9
Long-term treatment of depression. Keller, Suppl 17, 41–45
Major depression in 1998: are we providing optimal therapy? Angst, Suppl 6, 5–9
Management of anxious depression in primary care. Goldberg D, Suppl 7, 39–42
Mirtazapine augmentation in the treatment of refractory depression. Carpenter, Jan 45–49
Mirtazapine in major depression with comorbid generalized anxiety disorder. Goodnick, July 446–448
Mood-stabilizing drugs in depression. Shelton, Suppl 5, 37–40
Multicenter, placebo-controlled, fixed-dose study of citalopram in moderate-to-severe depression. Feighner, Dec 824–830
New antipsychotic agents: emerging clinical profiles. Buckley, Suppl 1, 12–17
New developments in the treatment of depression. Montgomery, Suppl 14, 10–15
Obsessions and compulsions in women with postpartum depression. Wisner, Mar 176–180
Olanzapine response in psychotic depression. Rothschild, Feb 116–118
Once-daily venlafaxine extended release (XR) compared with fluoxetine in outpatients with depression and anxiety. Silverstone, Jan 22–28
Patient with comorbid depression and anxiety: the unmet need. Bakish, Suppl 6, 20–24
Pharmacokinetic considerations of antidepressant use in the elderly. DeVane, Suppl 20, 38–44
Pharmacotherapy of depressive illness in adolescents: open-label comparison of fluoxetine with imipramine-treated historical controls. Strober, Mar 164–169
Practical considerations for the treatment of depression in elderly and very elderly long-term care patients. Salzman, Suppl 20, 30–33
Primary care issues related to the treatment of depression in elderly patients. Montano, Suppl 20, 45–51
Psychotic subtyping of major depressive disorder and posttraumatic stress disorder. Zimmerman, May 311–314
Reboxetine, a unique selective NRI, prevents relapse and recurrence in long-term treatment of major depressive disorder. Versiani, June 400–406
Redefining antidepressant efficacy toward long-term recovery. Thase, Suppl 6, 15–19
Relationship between borderline personality disorder and axis I diagnosis in severity of depression and anxiety. Comtois, Nov 752–758
Residual symptoms in depressed patients who respond acutely to fluoxetine. Nierenberg, Apr 221–225
Role of Norepinephrine in the Treatment of Depression [ACADEMIC HIGHLIGHTS]. Sept 623–631
Safety and feasibility of repetitive transcranial magnetic stimulation in the treatment of anxious depression in pregnancy: a case report. Nahas, Jan 50–52
Strategies and tactics in the management of maintenance treatment for depressed patients. Rush, Suppl 14, 21–26
Structural issues and policy in the primary care management of depression. Magruder, Suppl 7, 45–51
Suicide attempts in major affective disorder patients with comorbid substance use disorders. Tondo, Suppl 2, 63–69
Suicide risk in patients with major depressive disorder. Angst, Suppl 2, 57–62
Texas Medication Algorithm Project: report of the Texas Consensus Conference Panel on Medication Treatment of Major Depressive Disorder. Crismon, Mar 142–156
Treatment of depression in patients with heart disease. Roose, Suppl 20, 34–37
Treatment of major depression: is improvement enough? Ferrier, Suppl 6, 10–14
Treatment options for refractory depression. Shelton, Suppl 4, 57–61
Two-year maintenance treatment with citalopram, 20 mg, in unipolar subjects with high recurrence rate. Franchini, Dec 861–865
Underrecognition and undertreatment of depression: what is the breadth and depth of the problem? Davidson, Suppl 7, 4–9
Zolpidem for persistent insomnia in SSRI-treated depressed patients. Asnis, Oct 668–676
Developmental Disorders
Aggressive behavior in patients with attention-deficit/hyperactivity disorder, conduct disorder, and pervasive developmental disorders. Weller, Suppl 15, 5–11
Diabetes Mellitus
New-onset diabetes mellitus associated with the initiation of quetiapine treatment [letter]. Sobel, Aug 556–557
Diagnosis and Classification
Reliability and validity of a screening questionnaire for 13 DSM-IV axis I disorders (the Psychiatric Diagnostic Screening Questionnaire) in psychiatric outpatients. Zimmerman, Oct 677–683
Diazepam
Transient syncope and ECG-changes associated with the concurrent administration of clozapine and diazepam [letter]. Tupala, Sept 619–620
Diet
Refining the MAOI diet: tyramine content of pizzas and soy products. Shulman, Mar 191–193

Differential Diagnosis
Bipolar II disorder vs. premenstrual dysphoric disorder [letter]. Macmillan, June 409–410
History, epidemiology, and differential diagnosis of social anxiety disorder. Moutier, Suppl 9, 4–8
Dissociative Identity Disorder
Upper-extremity self-amputation in a case of dissociative identity disorder [letter]. Brenner; Schlozman reply, Oct 705–706
Divalproex see Valproate
Donepezil
Donepezil for psychotropic-induced memory loss. Jacobsen, Oct 698–704
Donepezil overdose [letter]. Greene, Jan 56–57
Driving
Effects of cannabis use on cognitive functions and driving ability. Kurzthaler, June 395–399
Droperidol
Droperidol: efficacy and side effects in psychiatric emergencies. Chambers, Oct 664–667
Drug Discontinuation
Antidepressant discontinuation–related mania: critical prospective observation and theoretical implications in bipolar disorder [CME]. Goldstein, Aug 563–567
Pharmacists lack knowledge of antidepressant discontinuation symptoms [letter]. Haddad; Young reply, Feb 124–125
Withdrawal from controlled carbamazepine therapy followed by further carbamazepine treatment in patients with dementia. Tariot, Oct 684–689
Drug Therapy, Combination
Chromium potentiation of antidepressant pharmacotherapy for dysthymic disorder in 5 patients. McLeod, Apr 237–240
Do depressed subjects who have failed both fluoxetine and a tricyclic respond to the combination? Levitt, Sept 613–616
Early augmentation of sertraline with methylphenidate [letter]. Postolache, Feb 123–124
Lithium augmentation fails to reduce symptoms in poorly responsive schizophrenic outpatients. Schulz, June 366–372
Mirtazapine augmentation in the treatment of refractory depression. Carpenter, Jan 45–49
Risperidone augmentation of selective serotonin reuptake inhibitors in major depression. Ostroff, Apr 256–259
Treatment options for refractory depression. Shelton, Suppl 4, 57–61
Dyskinesia
Associations between cognitive impairment and tardive dyskinesia: another perspective. Dodge, Suppl 13, 17–21
Chorea and tardive dyskinesia in a patient on risperidone [letter]. Carroll, July 485–487
Choreiform dyskinesia with acute onset and protracted course following fluoxetine treatment [letter]. Nielsen, Dec 868–869
Quetiapine in the management of treatment-emergent tardive dyskinesia and parkinsonian side effects: a case report. Green, Suppl 23, 21–22
Risperidone treatment of tardive dyskinesia and dystonia [letter]. Chong, May 340–341
Tardive dyskinesia associated with olanzapine monotherapy [letter]. Ananth, Dec 870
Tardive dyskinesia in affective disorders. Kane, Suppl 5, 43–47
Dysthymia
Chromium potentiation of antidepressant pharmacotherapy for dysthymic disorder in 5 patients. McLeod, Apr 237–240
Long-term outcome of dysthymia in private practice: clinical features, temperament, and the art of management. Haykal, Aug 508–518
Venlafaxine in the treatment of dysthymia: an open-label study. Hellerstein, Dec 845–849
Dystonia
Reserpine treatment of comorbid Tourette's disorder and tardive dystonia [letter]. Rojas, Oct 709–710
Risperidone treatment of tardive dyskinesia and dystonia [letter]. Chong, May 340–341
"Ecstasy"
Effects of "Ecstasy" blocked by serotonin reuptake inhibitors [letter]. Stein, July 485
Elderly
Adverse reactions of antidepressants in elderly patients. Pollock, Suppl 20, 4–8
Associations between cognitive impairment and tardive dyskinesia: another perspective. Dodge, Suppl 13, 17–21
Cognitive effects of paroxetine in older depressed patients. Nebes, Suppl 20, 26–29
Cognitive functioning in late-life schizophrenia: its importance and implications for overall outcome. Harvey, Suppl 13, 10–16
Continuation and maintenance pharmacotherapy in geriatric depression: an open-trial comparison of paroxetine and nortriptyline in patients older than 70 years. Walters, Suppl 20, 21–25
Double-blind randomized comparison of nortriptyline and paroxetine in the treatment of late-life depression: 6-week outcome. Mulsant, Suppl 20, 16–20
Effectiveness of antidepressants in elderly depressed outpatients: a prospective case series study. Mittmann, Oct 690–697
Efficacy and safety of clozapine versus chlorpromazine in geriatric schizophrenia. Howanitz, Jan 41–44
Efficacy of lithium vs. valproate in the treatment of mania in the elderly: a retrospective study. Chen, Mar 181–186
Efficacy, safety, and tolerability of antipsychotics in the elderly. Maixner, Suppl 8, 29–41
Epidemiology and diagnosis of depression in late life. Mulsant, Suppl 20, 9–15
Evaluation and management of aggressive behavior in the elderly demented patient. Raskind, Suppl 15, 45–49
Half century of psychosis: a case report describing the ethical dilemma of treating an elderly patient with long-term schizophrenia. Yorston, Suppl 23, 31–33
Introduction. Awakening psychiatry to geriatrics: Finagle, Osler, and Ginger Rogers. Tariot, Suppl 8, 3
Introduction: newer drugs for older patients. Jeste, Suppl 13, 3–4
Management of psychosis and agitation in elderly patients: a primary care perspective. Bulow, Suppl 13, 22–25
Older patient: the ongoing challenge of efficacy and tolerability. Tariot, Suppl 23, 29–30
Pharmacokinetic considerations of antidepressant use in the elderly. DeVane, Suppl 20, 38–44
Practical considerations for the treatment of depression in elderly and very elderly long-term care patients. Salzman, Suppl 20, 30–33
Primary care issues related to the treatment of depression in elderly patients. Montano, Suppl 20, 45–51
Psychopharmacology of atypical antipsychotics and clinical outcomes in elderly patients. Kumar, Suppl 13, 5–9
Psychoses in the elderly: a spectrum of disorders. Targum, Suppl 8, 4–10
Quetiapine, a novel antipsychotic: experience in elderly patients with psychotic disorders. McManus, May 292–298
Electroconvulsive Therapy (ECT)
ECT-induced premature labor: a case report [letter]. Polster, Jan 53–54
Electroconvulsive therapy and suicide risk. Prudic, Suppl 2, 104–110
Emergency Psychiatry
Droperidol: efficacy and side effects in psychiatric emergencies. Chambers, Oct 664–667
Ethics
Legal and ethical considerations in the treatment of psychosis. Fitzgerald WL Jr, Suppl 19, 59–65
Expert Consensus Guideline Series
Treatment of Posttraumatic Stress Disorder. Foa (ed), Suppl 16, 1–76
Treatment of Schizophrenia 1999. McEvoy (ed), Suppl 11, 1–80
Extrapyramidal Symptoms
Continuing problem of extrapyramidal symptoms: strategies for avoidance and effective treatment. Gerlach, Suppl 23, 20–24
Fertility
Fertility and reproduction in women with anorexia nervosa: a controlled study [CME]. Bulik, Feb 130–135
Fluoxetine
Changes in adverse events reported by patients during 6 months of fluoxetine therapy. Zajecka, June 389–394
Choreiform dyskinesia with acute onset and protracted course following fluoxetine treatment [letter]. Nielsen, Dec 868–869
Comparing the efficacy and safety of fluoxetine and venlafaxine in outpatient depression [letter]. Michelson; Costa e Silva reply, May 338–340
Do depressed subjects who have failed both fluoxetine and a tricyclic respond to the combination? Levitt, Sept 613–616
Emergence of social phobia during clozapine treatment and its response to fluoxetine augmentation. Pallanti, Dec 819–823
Once-daily venlafaxine extended release (XR) compared with fluoxetine in outpatients with depression and anxiety. Silverstone, Jan 22–28
Once-daily venlafaxine XR compared with fluoxetine in outpatients with depression and anxiety [letter]. Judge; Silverstone reply, Nov 795–796
Once-weekly dosing of fluoxetine in the maintenance of remission in panic disorder. Emmanuel, May 299–301
Pharmacotherapy of depressive illness in adolescents: open-label comparison of fluoxetine with imipramine-treated historical controls. Strober, Mar 164–169
Residual symptoms in depressed patients who respond acutely to fluoxetine. Nierenberg, Apr 221–225
Venlafaxine versus fluoxetine [letter]. Paton, Oct 708
Flutamide
Open trial of flutamide for treatment of obsessive-compulsive disorder. Altemus, July 442–445
Fluvoxamine
Deliberate self-poisoning following fluvoxamine-neuroleptics combination [letter]. Chong, Dec 869
Efficacy of fluvoxamine in the treatment of major depression with comorbid anxiety disorders. Sonawalla, Sept 580–583

Improved outcome in fluvoxamine-treated patients with SSRI-induced sexual dysfunction [letter]. Banov; Nafziger reply, Dec 866–867
Incidence of sexual dysfunction in healthy volunteers on fluvoxamine therapy. Nafziger, Mar 187–190
Gabapentin
Case report of reduction in alcohol craving and protection against alcohol withdrawal by gabapentin [letter]. Chatterjee, Sept 617
Clinical experience with gabapentin in patients with bipolar or schizoaffective disorder: results of an open-label study. Cabras, Apr 245–248
Gender
Effects of gender and age on plasma levels of clozapine and its metabolites: analyzed by critical statistics. Lane, Jan 36–40
Gender differences in the epidemiology and treatment of anxiety disorders. Pigott, Suppl 18, 4–15
Gender differences in the presentation and management of social anxiety disorder. Weinstock, Suppl 9, 9–13
Gender-related clinical differences in older patients with schizophrenia [CME]. Lindamer, Jan 61–67
Gene Expression
Modulation of CNS signal transduction pathways and gene expression by mood-stabilizing agents: therapeutic implications. Manji, Suppl 2, 27–39
Generalized Anxiety Disorder
Mirtazapine in major depression with comorbid generalized anxiety disorder. Goodnick, July 446–448
Sensitivity to 35% carbon dioxide in patients with generalized anxiety disorder. Perna, June 379–384
Venlafaxine extended release (XR) in the treatment of generalized anxiety disorder. Sheehan, Suppl 22, 23–28
Genetics
Genetics of suicide in depression. Roy, Suppl 2, 12–17
Geriatric Psychiatry see Elderly
Glucose
Different influences of classical antipsychotics and clozapine on glucose-insulin homeostasis in patients with schizophrenia or related psychoses. Melkersson, Nov 783–791
Granulocytopenia
Olanzapine treatment after clozapine-induced granulocytopenia in 3 patients. Swartz, Feb 119–121
Guidelines see also Consensus Statements
Clinical practice guidelines for bipolar disorder from the Department of Veterans Affairs. Bauer, Jan 9–21
Clinical practice guidelines: praise and problems. Sachs, Jan 7–8
Haloperidol
Changes in perceived health and functioning as a cost-effectiveness measure for olanzapine versus haloperidol treatment of schizophrenia. Tunis, Suppl 19, 38–46
Effectiveness of antipsychotic therapy in a naturalistic setting: a comparison between risperidone, perphenazine, and haloperidol. Coley, Dec 850–856
Recommended haloperidol and risperidone doses in first-episode psychosis [letter]. McGorry; DeQuardo reply, Nov 794–795
Heart Disease
Treatment of depression in patients with heart disease. Roose, Suppl 20, 34–37
HIV
Antidepressant efficacy in HIV-seropositive outpatients with major depressive disorder: an open trial of nefazodone. Elliott, Apr 226–231
Antidepressant treatment of depression in HIV-seropositive women. Ferrando, Nov 741–746
Hoarding
Hoarding in obsessive-compulsive disorder: a report of 20 cases. Winsberg, Sept 591–597
Hyperammonemia
Valproate-induced hyperammonemia in the psychiatric setting: 2 cases [letter]. Panikkar, Aug 557–559
Hyperprolactinemia
Hyperprolactinemia and male sexual dysfunction [letter]. Dickson, Feb 125
Hypothyroidism
Lithium-induced subclinical hypothyroidism: review of the literature and guidelines for treatment. Kleiner, Apr 249–255
Ileus
Ileus as a possible result of bupropion in an elderly woman [letter]. Kales, May 337
Illinois
Clozapine for refractory schizophrenia: the Illinois experience. Buckman, Suppl 1, 18–22
Imipramine
Pharmacotherapy of depressive illness in adolescents: open-label comparison of fluoxetine with imipramine-treated historical controls. Strober, Mar 164–169
Impulse Control Disorders
Study of impulse-control disorders among alcohol-dependent patients. Lejoyeux, May 302–305
Insomnia
Antidepressant treatment of the depressed patient with insomnia. Thase, Suppl 17, 28–31
Paroxetine for primary insomnia: possible placebo effect? [letter] Musa, Nov 795
Paroxetine in the treatment of primary insomnia: preliminary clinical and electroencephalogram sleep data. Nowell, Feb 89–95
Zolpidem for persistent insomnia in SSRI-treated depressed patients. Asnis, Oct 668–676
Insulin
Different influences of classical antipsychotics and clozapine on glucose-insulin homeostasis in patients with schizophrenia or related psychoses. Melkersson, Nov 783–791
Intermittent Explosive Disorder
Recognition and treatment of DSM-IV intermittent explosive disorder. McElroy, Suppl 15, 12–16
Treatment of intermittent explosive disorder with sertraline in 3 patients [letter]. Feder, Mar 195–196
Isotretinoin
Isotretinoin treatment of a woman with bipolar disorder [letter]. Wisner, June 407–408
Journal of Clinical Psychiatry
Annual gratitude [editorial]. Gelenberg, Feb 74–76
Manufacturer support and outcome [letter]. Mandelkern; Gelenberg reply, Feb 122–123
Millennial musings [editorial]. Gelenberg, Nov 730
Our sixtieth year [editorial]. Jan 3–4
Physicians Postgraduate Press earns full 4-year CME accreditation [editorial]. May 281
Kleptomania
Treatment of kleptomania with paroxetine [letter]. Kraus, Nov 793
Labor Onset/Pregnancy
ECT-induced premature labor: a case report [letter]. Polster, Jan 53–54
Lamotrigine
Double-blind, placebo-controlled study of lamotrigine monotherapy in outpatients with bipolar I depression. Calabrese, Feb 79–88
Lamotrigine as prophylaxis against steroid-induced mania [letter]. Preda, Oct 708–709
Law
Legal and ethical considerations in the treatment of psychosis. Fitzgerald WL Jr, Suppl 19, 59–65
Light Therapy see Phototherapy
Lithium
Effects of chronic lithium treatment on the peripheral nervous system. Faravelli, May 306–310
Effects of lithium treatment and its discontinuation on suicidal behavior in bipolar manic-depressive disorders. Baldessarini, Suppl 2, 77–84
Efficacy of lithium vs. valproate in the treatment of mania in the elderly: a retrospective study. Chen, Mar 181–186
Lithium augmentation fails to reduce symptoms in poorly responsive schizophrenic outpatients. Schulz, June 366–372
Lithium-induced subclinical hypothyroidism: review of the literature and guidelines for treatment. Kleiner, Apr 249–255
Lithium therapy and suicide risk. Nilsson, Suppl 2, 85–88
Modulation of CNS signal transduction pathways and gene expression by mood-stabilizing agents: therapeutic implications. Manji, Suppl 2, 27–39
Lorazepam
Seizures after discontinuation of low-dose lorazepam from originally seizure-free clozapine regimen: combined effects? [letter] Lane, June 408–409
Loxapine
Does loxapine have "atypical" properties? clinical evidence. Glazer, Suppl 10, 42–46
Low-dose loxapine in the treatment of schizophrenia: is it more effective and more "atypical" than standard-dose loxapine? Meltzer HY, Suppl 10, 47–51
Maintenance Treatment
Patient's coping skills and environmental stress important to understanding recurrence during antidepressant maintenance [letter]. Hart, Aug 556
Managed Care
Capitation [letter]. Sheeley; Glazer reply, Jan 54–55
Cost of treating mental illness from a managed care perspective. Docherty, Suppl 3, 49–52
Mania
Antidepressant discontinuation–related mania: critical prospective observation and theoretical implications in bipolar disorder [CME]. Goldstein, Aug 563–567
Efficacy of lithium vs. valproate in the treatment of mania in the elderly: a retrospective study. Chen, Mar 181–186
Lamotrigine as prophylaxis against steroid-induced mania [letter]. Preda, Oct 708–709
Management of acute mania. Tohen, Suppl 5, 31–34
Rap and mania [letter]. Markowitz, Aug 554–555
Tiagabine appears not to be efficacious in the treatment of acute mania. Grunze, Nov 759–762
Medicaid
Use patterns for antipsychotic medications in Medicaid patients with schizophrenia. McCombs, Suppl 19, 5–13

Medical Illness
Depression in the medical setting: biopsychological interactions and treatment considerations. Evans DL, Suppl 4, 40–55
Medical illness in patients with schizophrenia. Goldman, Suppl 21, 10–15
Suicide, assisted suicide, and medical illness. Hendin, Suppl 2, 46–50
Melancholia
Antidepressant effectiveness in severe depression and melancholia. Schatzberg, Suppl 4, 14–21
Memory Loss
Donepezil for psychotropic-induced memory loss. Jacobsen, Oct 698–704
Men
Hyperprolactinemia and male sexual dysfunction [letter]. Dickson, Feb 125
Psychiatric features of 36 men convicted of sexual offenses [CME]. McElroy, June 414–420
Mental Health Services
Effectiveness of combining atypical antipsychotics and psychosocial rehabilitation in a community mental health center setting. Noordsy, Suppl 19, 47–53
Mental health care from the public perspective: the Texas Medication Algorithm Project. Shon, Suppl 3, 16–20
Mental Illness see Psychopathology
Methamphetamine
Methamphetamine-associated obsessional symptoms and effective risperidone treatment: a case report [letter]. Iyo, May 337–338
Methylphenidate
Early augmentation of sertraline with methylphenidate [letter]. Postolache, Feb 123–124
Metrifonate
Effects of metrifonate on the cognitive, behavioral, and functional performance of Alzheimer's disease patients. Raskind, May 318–325
Metrifonate: update on a new antidementia agent. Ringman, Nov 776–782
Mirtazapine
Mirtazapine: clinical overview. Gorman, Suppl 17, 9–13
Mirtazapine: other indications. Falkai, Suppl 17, 36–40
Mirtazapine augmentation in the treatment of refractory depression. Carpenter, Jan 45–49
Mirtazapine in major depression with comorbid generalized anxiety disorder. Goodnick, July 446–448
Mirtazapine versus selective serotonin reuptake inhibitors. Thompson, Suppl 17, 18–22
Relief of SSRI-induced sexual dysfunction with mirtazapine treatment [letter]. Farah, Apr 260–261
Monoamine Oxidase Inhibitors
Refining the MAOI diet: tyramine content of pizzas and soy products. Shulman, Mar 191–193
Mood
Anticonvulsant therapy and suicide risk in affective disorders. Goodwin, Suppl 2, 89–93
Should we consider mood disturbance in schizophrenia as an important determinant of quality of life? Tollefson, Suppl 5, 23–29
Tardive dyskinesia in affective disorders. Kane, Suppl 5, 43–47
Mood Stabilizers
Introduction: use of mood stabilizers in the treatment of psychiatric disorders. Bowden, Suppl 5, 3–4
Management of acute mania. Tohen, Suppl 5, 31–34
Mood stabilizers and the evolution of maintenance study designs in bipolar I disorder. Calabrese, Suppl 5, 5–13
Mood-stabilizing drugs in depression. Shelton, Suppl 5, 37–40
Overview of the treatment of schizoaffective disorder. McElroy, Suppl 5, 16–21
Use of Mood Stabilizers for Treating Psychiatric Disorders, Suppl 5, 1–52
Naltrexone
Measurement of compliance with naltrexone in the treatment of alcohol dependence: clinical and research implications. Namkoong, July 449–453
Naltrexone in the treatment of dissociative symptoms in patients with borderline personality disorder: an open-label trial. Schmahl, Sept 598–603
Nefazodone
Nefazodone in social phobia. Van Ameringen, Feb 96–100
Pharmacology of antidepressants: selectivity or multiplicity? Westenberg, Suppl 17, 4–8
Rapid fade of antidepressant effect of nefazodone in bipolar depression [letter]. El-Mallakh, Aug 559
Visual field "shimmering" associated with nefazodone [letter]. Greenberg WM, Feb 124
Neurobiology
Neurobiology of suicide risk: a review for the clinician. Mann, Suppl 2, 7–11
Neuropeptides
Peptides and psychiatry, part 1: how synthesis of neuropeptides differs from classical neurotransmitter synthesis. Stahl, Jan 5–6
Peptides and psychiatry, part 2: substance P and the neurokinins: novel peptide neurotransmitters in psychopharmacology. Stahl, Feb 77–78
Peptides and psychiatry, part 3: substance P and serendipity: novel psychotropics are a possibility. Stahl, Mar 140–141
Neurotransmitters
Models of antidepressant action. Berman, Suppl 14, 16–20
Pharmacology of antidepressants: selectivity or multiplicity? Westenberg, Suppl 17, 4–8
New Drug Application
How should efficacy be evaluated in randomized clinical trials of treatments for depression? Thase, Suppl 4, 23–31
Norepinephrine
The Role of Norepinephrine in the Treatment of Depression [Academic Highlights]. Sept 623–631
Nortriptyline
Continuation and maintenance pharmacotherapy in geriatric depression: an open-trial comparison of paroxetine and nortriptyline in patients older than 70 years. Walters, Suppl 20, 21–25
Double-blind randomized comparison of nortriptyline and paroxetine in the treatment of late-life depression: 6-week outcome. Mulsant, Suppl 20, 16–20
Obsessive-Compulsive Disorder
Clinical features, psychiatric comorbidity, and health-related quality of life in persons reporting compulsive computer use behavior. Black, Dec 839–844
Cognitive-behavioral therapy as an adjunct to serotonin reuptake inhibitors in obsessive-compulsive disorder: an open trial. Simpson HB, Sept 584–590
Hoarding in obsessive-compulsive disorder: a report of 20 cases. Winsberg, Sept 591–597
Home self-assessment and self-treatment of obsessive-compulsive disorder using a manual and a computer-conducted telephone interview: replication of a U.K.-U.S. study. Bachofen, Aug 545–549
Managing aggressive behavior in patients with obsessive-compulsive disorder and borderline personality disorder. Hollander, Suppl 15, 38–44
Obsessions and compulsions in women with postpartum depression. Wisner, Mar 176–180
Obsessive-compulsive disorder: diagnosis and treatment. Goodman, Suppl 18, 27–32
Obsessive-compulsive symptoms with risperidone [letter]. Mahendran; Andrade C reply, Saxena reply, Apr 261–263
Olanzapine addition in obsessive-compulsive disorder refractory to selective serotonin reuptake inhibitors: an open-label case series. Weiss, Aug 524–527
Open trial of flutamide for treatment of obsessive-compulsive disorder. Altemus, July 442–445
Patterns of remission and relapse in obsessive-compulsive disorder: a 2-year prospective study. Eisen, May 346–351
Review of the efficacy of selective serotonin reuptake inhibitors in obsessive-compulsive disorder. Pigott, Feb 101–106
Risperidone augmentation of paroxetine in a case of severe, treatment-refractory obsessive-compulsive disorder without comorbid psychopathology [letter]. Agid, Jan 55–56
Olanzapine
Changes in perceived health and functioning as a cost-effectiveness measure for olanzapine versus haloperidol treatment of schizophrenia. Tunis, Suppl 19, 38–46
Comparative effectiveness study of risperidone and olanzapine in the treatment of schizophrenia. Ho, Oct 658–663
Olanzapine addition in obsessive-compulsive disorder refractory to selective serotonin reuptake inhibitors: an open-label case series. Weiss, Aug 524–527
Olanzapine increases weight and serum triglyceride levels. Osser, Nov 767–770
Olanzapine response in psychotic depression. Rothschild, Feb 116–118
Olanzapine treatment after clozapine-induced granulocytopenia in 3 patients. Swartz, Feb 119–121
Tardive dyskinesia associated with olanzapine monotherapy [letter]. Ananth, Dec 870
Outcome
Annual health outcomes and treatment costs for schizophrenia populations. Mauskopf, Suppl 19, 14–22
Developing an outcomes-oriented approach for the treatment of schizophrenia. Lehman, Suppl 19, 30–37
Outpatients
Reliability and validity of a screening questionnaire for 13 DSM-IV axis I disorders (the Psychiatric Diagnostic Screening Questionnaire) in psychiatric outpatients. Zimmerman, Oct 677–683
Overdose
Donepezil overdose [letter]. Greene, Jan 56–57
Panic
Current concepts in the treatment of panic disorder. Sheehan, Suppl 18, 16–21
Efficacy, safety, and gradual discontinuation of clonazepam in panic disorder: a placebo-controlled, multicenter study using optimized dosages. Moroz, Sept 604–612

Environmental factors in panic disorder [letter]. Asnis, Apr 264
Once-weekly dosing of fluoxetine in the maintenance of remission in panic disorder. Emmanuel, May 299–301
Panic disorder in the primary care setting: comorbidity, disability, service utilization, and treatment [CME]. Roy-Byrne, July 492–499
Paroxetine, clomipramine, and cognitive therapy in the treatment of panic disorder. Bakker, Dec 831–838
Response to missile attacks on civilian targets in patients with panic disorder. Sasson, June 385–388

Parkinson's Disease
Management of psychotic aspects of Parkinson's disease. Juncos, Suppl 8, 42–53
Quetiapine in the management of treatment-emergent tardive dyskinesia and parkinsonian side effects: a case report. Green, Suppl 23, 21–22
SSRI-induced parkinsonism may be an earlier sign of future Parkinson's disease [letter]. Gönül, June 410

Paroxetine
Cognitive effects of paroxetine in older depressed patients. Nebes, Suppl 20, 26–29
Continuation and maintenance pharmacotherapy in geriatric depression: an open-trial comparison of paroxetine and nortriptyline in patients older than 70 years. Walters, Suppl 20, 21–25
Double-blind randomized comparison of nortriptyline and paroxetine in the treatment of late-life depression: 6-week outcome. Mulsant, Suppl 20, 16–20
Excretion of paroxetine into breast milk. Öhman, Aug 519–523
Paroxetine, clomipramine, and cognitive therapy in the treatment of panic disorder. Bakker, Dec 831–838
Paroxetine for primary insomnia: possible placebo effect? [letter] Musa, Nov 795
Paroxetine in the treatment of primary insomnia: preliminary clinical and electroencephalogram sleep data. Nowell, Feb 89–95
Risperidone augmentation of paroxetine in a case of severe, treatment-refractory obsessive-compulsive disorder without comorbid psychopathology [letter]. Agid, Jan 55–56
Treatment of kleptomania with paroxetine [letter]. Kraus, Nov 793

Pathophysiology
Pathophysiologic mechanisms in the pathogenesis and clinical course of schizophrenia. Lieberman, Suppl 12, 9–12

Patient Care
What about the patient? Weisburd, Suppl 3, 38–41

Peripheral Nervous System
Effects of chronic lithium treatment on the peripheral nervous system. Faravelli, May 306–310

Perphenazine
Effectiveness of antipsychotic therapy in a naturalistic setting: a comparison between risperidone, perphenazine, and haloperidol. Coley, Dec 850–856

Pharmacists
Pharmacists lack knowledge of antidepressant discontinuation symptoms [letter]. Haddad; Young reply, Feb 124–125
Role of neuropsychiatric pharmacists. Cohen, Suppl 19, 54–58

Pharmacokinetics
Pharmacologic and pharmacokinetic considerations in choosing an antipsychotic. Ereshefsky, Suppl 10, 20–30

Pharmacology
Antipsychotics from theory to practice: integrating clinical and basic data. Tandon, Suppl 8, 21–28
D_2 and 5-HT_2 receptor effects of antipsychotics: bridging basic and clinical findings using PET. Remington, Suppl 10, 15–19
Pharmacologic and pharmacokinetic considerations in choosing an antipsychotic. Ereshefsky, Suppl 10, 20–30
Receptor pharmacology of neuroleptics: relation to clinical effects. Richelson, Suppl 10, 5–14

Phototherapy
Bright light therapy: side effects and benefits across the symptom spectrum. Terman, Nov 799–808

Physician-Patient Relations
Compliance and the rehabilitation alliance. Aquila, Suppl 19, 23–29

Polydipsia
Anetholtrithion stabilizes body weight fluctuation caused by excessive water drinking in a patient with schizophrenia: a case report [letter]. Matsuo, Oct 706

Positron Emission Tomography
D_2 and 5-HT_2 receptor effects of antipsychotics: bridging basic and clinical findings using PET. Remington, Suppl 10, 15–19

Posttraumatic Stress Disorder
Defining psychosis in PTSD [letter]. Pies; David reply, Aug 555–556
Management of posttraumatic stress disorder: diagnostic and therapeutic issues. Davidson, Suppl 18, 33–38
Managing anger and aggression in patients with posttraumatic stress disorder. Yehuda, Suppl 15, 33–37
Psychotic subtyping of major depressive disorder and posttraumatic stress disorder. Zimmerman, May 311–314
Psychotic symptoms in combat-related post-traumatic stress disorder. David, Jan 29–32
Treatment of Posttraumatic Stress Disorder [Expert Consensus Guideline Series]. Foa (ed), Suppl 16, 1–76

Pregnancy
Safety and teasibility of repetitive transcranial magnetic stimulation in the treatment of anxious depression in pregnancy: a case report. Nahas, Jan 50–52

Premenstrual Disorders
Bipolar II disorder vs. premenstrual dysphoric disorder [letter]. Macmillan, June 409–410
Follow-up study of premenstrual syndrome. Roca, Nov 763–766

Prescriptions, Drug
Risperidone use at a state hospital: a clinical audit 2 years after the first wave of risperidone prescriptions. Chengappa, June 373–378

Primary Care
Best clinical practice: guidelines for managing major depression in primary medical care. Schulberg, Suppl 7, 19–26
Comorbidity in primary care: presentation and consequences. Wittchen, Suppl 7, 29–36
Consensus statement on the primary care management of depression from the International Consensus Group on Depression and Anxiety. Ballenger, Suppl 7, 54–61
Depression in the community: physician and patient perspective. Tylee, Suppl 7, 12–16
Introduction: focus on primary care management of depression. Ballenger, Suppl 7, 3
Management of anxious depression in primary care. Goldberg D, Suppl 7, 39–42
Management of psychosis and agitation in elderly patients: a primary care perspective. Bulow, Suppl 13, 22–25
Panic disorder in the primary care setting: comorbidity, disability, service utilization, and treatment. Roy-Byrne, July 492–499
Primary care issues related to the treatment of depression in elderly patients. Montano, Suppl 20, 45–51
Structural issues and policy in the primary care management of depression. Magruder, Suppl 7, 45–51

Primates
Primate models to understand human aggression. Kalin, Suppl 15, 29–32

Private Practice
Long-term outcome of dysthymia in private practice: clinical features, temperament, and the art of management. Haykal, Aug 508–518

Protein Kinase C
Expression of the myristoylated alanine-rich C kinase substrate (MARCKS) and MARCKS-related protein (MRP) in the prefrontal cortex and hippocampus of suicide victims. McNamara, Suppl 2, 21–26
Modulation of CNS signal transduction pathways and gene expression by mood-stabilizing agents: therapeutic implications. Manji, Suppl 2, 27–39

Psychiatric Diagnostic Screening Questionnaire
Reliability and validity of a screening questionnaire for 13 DSM-IV axis I disorders (the Psychiatric Diagnostic Screening Questionnaire) in psychiatric outpatients. Zimmerman, Oct 677–683

Psychopathology
Medication treatment for the severely and persistently mentally ill: the Texas Medication Algorithm Project. Rush, May 284–291
Night terrors, sleepwalking, and confusional arousals in the general population: their frequency and relationship to other sleep and mental disorders [CME]. Ohayon, Apr 268–276

Psychopharmacology
Mechanism of action of antidepressant medications. Feighner, Suppl 4, 4–11

Psychosis see also specific diagnoses
Clozapine and obsessions in patients with recent-onset schizophrenia and other psychotic disorders. de Haan, June 364–365
Defining psychosis in PTSD [letter]. Pies; David reply, Aug 555–556
Legal and ethical considerations in the treatment of psychosis. Fitzgerald WL Jr, Suppl 19, 59–65
Management of psychosis and agitation in elderly patients: a primary care perspective. Bulow, Suppl 13, 22–25
Management of psychotic aspects of Parkinson's disease. Juncos, Suppl 8, 42–53
Pharmacologic management of psychosis in dementia. Schneider, Suppl 8, 54–60
Psychoses in the elderly: a spectrum of disorders. Targum, Suppl 8, 4–10
Psychotic symptoms in combat-related post-traumatic stress disorder. David, Jan 29–32
Quetiapine, a novel antipsychotic: experience in elderly patients with psychotic disorders. McManus, May 292–298

Recommended haloperidol and risperidone doses in first-episode psychosis [letter]. McGorry; DeQuardo reply, Nov 794–795
Risperidone for the treatment of monosymptomatic hypochondriacal psychosis [letter]. Çetin, Aug 554
Psychotropic Drugs
Medication treatment for the severely and persistently mentally ill: the Texas Medication Algorithm Project. Rush, May 284–291
Mergers and acquisitions among psychotropics: antidepressant takeover of anxiety may now be complete. Stahl, May 282–283
Weight gain associated with use of psychotropic medications. Sachs, Suppl 21, 16–19
Quality of Life
Should we consider mood disturbance in schizophrenia as an important determinant of quality of life? Tollefson, Suppl 5, 23–29
Wisconsin Quality of Life Index: a multidimensional model for measuring quality of life. Diamond, Suppl 3, 29–31
Quetiapine
Efficacy of quetiapine in relieving persistent symptoms in a patient with poor response to both conventional and atypical antipsychotic therapy. Koziupa, Suppl 23, 13
Long-term efficacy and tolerability of quetiapine in treatment-refractory schizophrenia: a case study. Reznik, Suppl 23, 16
New-onset diabetes mellitus associated with the initiation of quetiapine treatment [letter]. Sobel, Aug 556–557
Quetiapine, a novel antipsychotic: experience in elderly patients with psychotic disorders. McManus, May 292–298
Quetiapine and cognitive improvement in a patient with schizophrenia. Stip, Suppl 23, 27–28
Quetiapine in the management of treatment-emergent tardive dyskinesia and parkinsonian side effects: a case report. Green, Suppl 23, 21–22
Quetiapine in the psychosocial rehabilitation of a patient with chronic schizophrenia. Shaw, Suppl 23, 17–19
Rapid relief from the symptoms of schizophrenia with quetiapine: a case study. Lee, Suppl 23, 8–9
Symptom relief and improved social functioning following treatment with quetiapine in a schizophrenic patient with a history of poor response to antipsychotics. Freeman EB Sr, Suppl 23, 12
Use of quetiapine in first-episode schizophrenia: a case study. Jones, Suppl 23, 6–7
Utility of quetiapine in a patient with a history of poor response to previous treatment. Baird, Suppl 23, 15
Rap
Rap and mania [letter]. Markowitz, Aug 554–555
Rating Scales
Davidson Trauma Scale [Appendix 7]. Suppl 18, 80–82
Liebowitz Social Anxiety Scale [Appendix 3]. Suppl 18, 65
Mini-International Neuropsychiatric Interview [Appendix 1]. Suppl 18, 39–62
Sheehan Disability Scale [Appendix 4]. Suppl 18, 66
Sheehan Patient Rated Anxiety Scale [Appendix 2]. Suppl 18, 63–64
Treatment Outcome PTSD Scale [Appendix 6]. Suppl 18, 78–79
Yale-Brown Obsessive Compulsive Scale [Appendix 5]. Suppl 18, 67–77
Reboxetine
Reboxetine, a unique selective NRI, prevents relapse and recurrence in long-term treatment of major depressive disorder. Versiani, June 400–406
Relapse
Patterns of remission and relapse in obsessive-compulsive disorder: a 2-year prospective study. Eisen, May 346–351
Remission
Clinical guidelines for establishing remission in patients with depression and anxiety. Ballenger, Suppl 22, 29–34
Evolution of remission as the new standard in the treatment of depression. Nierenberg, Suppl 22, 7–11
Introduction: defining remission in patients treated with antidepressants. Thase, Suppl 22, 3–6
Summary: defining remission in patients treated with antidepressants. Thase, Suppl 22, 35–36
Research Support
Manufacturer support and outcome [letter]. Mandelkern; Gelenberg reply, Feb 122–123
Reserpine
Reserpine treatment of comorbid Tourette's disorder and tardive dystonia [letter]. Rojas, Oct 709–710
Restless Legs Syndrome
Treatment of restless legs syndrome with tramadol: an open study. Lauerma, Apr 241–244
Risperidone
Chorea and tardive dyskinesia in a patient on risperidone [letter]. Carroll, July 485–487
Clozapine versus risperidone in treatment-refractory schizophrenia: possible impact of dosing strategies [letter]. Lane, July 487–488
Comparative effectiveness study of risperidone and olanzapine in the treatment of schizophrenia. Ho, Oct 658–663
Comparison of risperidone and placebo for psychosis and behavioral disturbances associated with dementia: a randomized, double-blind trial. Katz, Feb 107–115
Dose-outcome analysis of risperidone. Love, Nov 771–775
Effectiveness of antipsychotic therapy in a naturalistic setting: a comparison between risperidone, perphenazine, and haloperidol. Coley, Dec 850–856
Methamphetamine-associated obsessional symptoms and effective risperidone treatment: a case report [letter]. Iyo, May 337–338
Obsessive-compulsive symptoms with risperidone [letter]. Mahendran; Andrade C reply, Saxena reply, Apr 261–263
Pilot study on risperidone metabolism: the role of cytochromes P450 2D6 and 3A. Bork, July 469–476
Recommended haloperidol and risperidone doses in first-episode psychosis [letter]. McGorry; DeQuardo reply, Nov 794–795
Risperidone and associated amenorrhea: a report of 5 cases. Kim, May 315–317
Risperidone augmentation of paroxetine in a case of severe, treatment-refractory obsessive-compulsive disorder without comorbid psychopathology [letter]. Agid, Jan 55–56
Risperidone augmentation of selective serotonin reuptake inhibitors in major depression. Ostroff, Apr 256–259
Risperidone for the treatment of monosymptomatic hypochondriacal psychosis [letter]. Çetin, Aug 554
Risperidone Outcomes Study of Effectiveness (ROSE): a model for evaluating treatment strategies in typical psychiatric practice. Mahmoud, Suppl 3, 42–47
Risperidone treatment of tardive dyskinesia and dystonia [letter]. Chong, May 340–341
Risperidone use at a state hospital: a clinical audit 2 years after the first wave of risperidone prescriptions. Chengappa, June 373–378
Treatment of inhalant abuse with risperidone [letter]. Misra, Sept 620
Safety
Clozapine: the commitment to patient safety. Alphs, Suppl 12, 39–42
Schizoaffective Disorder
Clinical experience with gabapentin in patients with bipolar or schizoaffective disorder: results of an open-label study. Cabras, Apr 245–248
Overview of the treatment of schizoaffective disorder. McElroy, Suppl 5, 16–21
Schizoaffective disorder: a form of schizophrenia or affective disorder? [CME] Evans JD, Dec 874–882
Schizophrenia
Anetholtrithion stabilizes body weight fluctuation caused by excessive water drinking in a patient with schizophrenia: a case report [letter]. Matsuo, Oct 706
Annual health outcomes and treatment costs for schizophrenia populations. Mauskopf, Suppl 19, 14–22
Changes in perceived health and functioning as a cost-effectiveness measure for olanzapine versus haloperidol treatment of schizophrenia. Tunis, Suppl 19, 38–46
Clinical heterogeneity between atypical antipsychotics in the treatment of schizophrenia: a case report. Taboada, Suppl 23, 23–24
Clozapine: a comparison with other novel antipsychotics. Fleischhacker, Suppl 12, 30–34
Clozapine: the commitment to patient safety. Alphs, Suppl 12, 39–42
Clozapine and obsessions in patients with recent-onset schizophrenia and other psychotic disorders. de Haan, June 364–365
Clozapine for refractory schizophrenia: the Illinois experience. Buckman, Suppl 1, 18–22
Clozapine versus risperidone in treatment-refractory schizophrenia: possible impact of dosing strategies [letter]. Lane, July 487–488
Cognitive dysfunction in schizophrenia and its importance to outcome: the place of atypical antipsychotics in treatment. Velligan, Suppl 23, 25–26
Cognitive functioning in late-life schizophrenia: its importance and implications for overall outcome. Harvey, Suppl 13, 10–16
Comparative effectiveness study of risperidone and olanzapine in the treatment of schizophrenia. Ho, Oct 658–663
Compliance and the rehabilitation alliance. Aquila, Suppl 19, 23–29
Conclusions. Learning from our patients: key issues in the clinical treatment of schizophrenia from a longitudinal perspective. Gerlach, Suppl 23, 34
Consensus discussion: clinical and economic issues of treatment-resistant schizophrenia. Suppl 1, 28–30

Continuing problem of extrapyramidal symptoms: strategies for avoidance and effective treatment. Gerlach, Suppl 23, 20–24
Cost-utility analysis in schizophrenia. Awad, Suppl 3, 22–26
Depressive and anxiety symptoms in patients with schizophrenia and schizophreniform disorder. Emsley, Nov 747–751
Developing an outcomes-oriented approach for the treatment of schizophrenia. Lehman, Suppl 19, 30–37
Different influences of classical antipsychotics and clozapine on glucose-insulin homeostasis in patients with schizophrenia or related psychoses. Melkersson, Nov 783–791
Distribution of body mass index among individuals with and without schizophrenia. Allison, Apr 215–220
Do antipsychotic medications decrease the risk of suicide in patients with schizophrenia? Palmer, Suppl 2, 100–103
Dose-outcome analysis of risperidone. Love, Nov 771–775
Economic impact of schizophrenia. Rice, Suppl 1, 4–6
Effects of clozapine on aggression and substance abuse in schizophrenic patients. Volavka, Suppl 12, 43–46
Effects of clozapine on cognitive functioning in schizophrenia. McGurk, Suppl 12, 24–29
Efficacy and safety of clozapine versus chlorpromazine in geriatric schizophrenia. Howanitz, Jan 41–44
Efficacy of quetiapine in relieving persistent symptoms in a patient with poor response to both conventional and atypical antipsychotic therapy. Koziupa, Suppl 23, 13
Evolving definition of treatment resistance. Peuskens, Suppl 12, 4–8
First-episode schizophrenia: the importance of early intervention and subjective tolerability. Kasper, Suppl 23, 5–9
Gender-related clinical differences in older patients with schizophrenia [CME]. Lindamer, Jan 61–67
Half century of psychosis: a case report describing the ethical dilemma of treating an elderly patient with long-term schizophrenia. Yorston, Suppl 23, 31–33
Historical perspective of clozapine. Hippius, Suppl 12, 22–23
Introduction. Learning from our patients: key issues in the clinical treatment of schizophrenia from a longitudinal perspective. Gerlach, Suppl 23, 3–4
Introduction: pharmacoeconomics of treatment-resistant schizophrenia. Hanson, Suppl 1, 3
Introduction. Treatment-resistant schizophrenia and beyond: current concepts and future prospects. Suppl 12, 3
Lithium augmentation fails to reduce symptoms in poorly responsive schizophrenic outpatients. Schulz, June 366–372
Long-term efficacy and tolerability of quetiapine in treatment-refractory schizophrenia: a case study. Reznik, Suppl 23, 16
Low-dose loxapine in the treatment of schizophrenia: is it more effective and more "atypical" than standard-dose loxapine? Meltzer HY, Suppl 10, 47–51
Management strategies for the treatment of schizophrenia. Kane, Suppl 12, 13–17
Medical illness in patients with schizophrenia. Goldman, Suppl 21, 10–15
Methods of cost-effectiveness analysis in the evaluation of new antipsychotics: implications for schizophrenia treatment. Neumann, Suppl 3, 9–14
New antipsychotic agents: emerging clinical profiles. Buckley, Suppl 1, 12–17
New vs. old antipsychotics: the Texas experience. Reid, Suppl 1, 23–25
Older patient: the ongoing challenge of efficacy and tolerability. Tariot, Suppl 23, 29–30
Optimizing clozapine treatment. Naber, Suppl 12, 35–38
Outcome in schizophrenia: beyond symptom reduction. Meltzer HY, Suppl 3, 3–7
Partial response to antipsychotic treatment: the patient with enduring symptoms. Emsley, Suppl 23, 10–11
Pathophysiologic mechanisms in the pathogenesis and clinical course of schizophrenia. Lieberman, Suppl 12, 9–12
Perspective and the measurement of costs and benefits for cost-effectiveness analysis in schizophrenia. Meltzer D, Suppl 3, 32–35
Pharmacoeconomic evaluation of treatments for refractory schizophrenia: clozapine-related studies. Revicki, Suppl 1, 7–11
Pharmacoeconomics of schizophrenia in the 21st century. Hanson, Suppl 1, 26–27
Quetiapine and cognitive improvement in a patient with schizophrenia. Stip, Suppl 23, 27–28
Quetiapine in the psychosocial rehabilitation of a patient with chronic schizophrenia. Shaw, Suppl 23, 17–19
Rapid relief from the symptoms of schizophrenia with quetiapine: a case study. Lee, Suppl 23, 8–9
Risperidone Outcomes Study of Effectiveness (ROSE): a model for evaluating treatment strategies in typical psychiatric practice. Mahmoud, Suppl 3, 42–47
Role of neuropsychiatric pharmacists. Cohen, Suppl 19, 54–58
Sexual offending and antisocial sexual behavior among patients with schizophrenia. Phillips, Mar 170–175
Should we consider mood disturbance in schizophrenia as an important determinant of quality of life? Tollefson, Suppl 5, 23–29
Some adverse effects of antipsychotics: prevention and treatment. Lader, Suppl 12, 18–21
Suicide and schizophrenia: clozapine and the InterSePT study. Meltzer HY, Suppl 12, 47–50
Suicide victims with schizophrenia in different treatment phases and adequacy of antipsychotic medication [CME]. Heilä, Mar 200–208
Symptom relief and improved social functioning following treatment with quetiapine in a schizophrenic patient with a history of poor response to antipsychotics. Freeman EB Sr, Suppl 23, 12
Texas Medication Algorithm Project (TMAP) schizophrenia algorithms. Miller, Oct 649–657
Treatment of Schizophrenia 1999 [Expert Consensus Guideline Series]. McEvoy (ed), Suppl 11, 1–80
Treatment-resistant schizophrenia: reviewing the options and identifying the way forward. Hellewell, Suppl 23, 14–19
Use of quetiapine in first-episode schizophrenia: a case study. Jones, Suppl 23, 6–7
Use patterns for antipsychotic medications in Medicaid patients with schizophrenia. McCombs, Suppl 19, 5–13
Utility of quetiapine in a patient with a history of poor response to previous treatment. Baird, Suppl 23, 15
What about the patient? Weisburd, Suppl 3, 38–41

Schizophreniform Disorder
Depressive and anxiety symptoms in patients with schizophrenia and schizophreniform disorder. Emsley, Nov 747–751

Schizotypal Personality Disorder
Clozapine for refractory schizophrenia: the Illinois experience. Buckman, Suppl 1, 18–22

Scientific Expert Meeting
Introduction: scientific expert meeting. Keller, Suppl 17, 3

Seasonal Affective Disorder
Bright light therapy: side effects and benefits across the symptom spectrum. Terman, Nov 799–808

Seizures
Seizures after discontinuation of low-dose lorazepam from originally seizure-free clozapine regimen: combined effects? [letter] Lane, June 408–409

Selective Serotonin Reuptake Inhibitors see also specific drugs
Antidepressant medication change in a clinical treatment setting: a comparison of the effectiveness of selective serotonin reuptake inhibitors. Nurnberg, Sept 574–579
Buspirone as an antidote to SSRI-induced bruxism in 4 cases. Bostwick, Dec 857–860
Effects of "Ecstasy" blocked by serotonin reuptake inhibitors [letter]. Stein, July 485
Efficacy of SSRIs and newer antidepressants in severe depression: comparison with TCAs. Hirschfeld, May 326–335
Mirtazapine versus selective serotonin reuptake inhibitors. Thompson, Suppl 17, 18–22
Relief of SSRI-induced sexual dysfunction with mirtazapine treatment [letter]. Farah, Apr 260–261
Review of the efficacy of selective serotonin reuptake inhibitors in obsessive-compulsive disorder. Pigott, Feb 101–106
Risperidone augmentation of selective serotonin reuptake inhibitors in major depression. Ostroff, Apr 256–259
Sildenafil for iatrogenic serotonergic antidepressant medication–induced sexual dysfunction in 4 patients. Nurnberg, Jan 33–35
Sildenafil treatment of serotonin reuptake inhibitor–induced sexual dysfunction [letter]. Ashton, Mar 194–195
SSRI-induced parkinsonism may be an earlier sign of future Parkinson's disease [letter]. Gönül, June 410
SSRIs and SNRIs: broad spectrum of efficacy beyond major depression. Gorman, Suppl 4, 33–38

Self-Assessment
Home self-assessment and self-treatment of obsessive-compulsive disorder using a manual and a computer-conducted telephone interview: replication of a U.K.-U.S. study. Bachofen, Aug 545–549

Self-Injurious Behavior
Clozapine reduces severe self-mutilation and aggression in psychotic patients with borderline personality disorder. Chengappa, July 477–484
Deliberate self-poisoning following fluvoxamine-neuroleptics combination [letter]. Chong, Dec 869
Self-amputation of left hand: a case report [letter]. Tavcar, Nov 793–794

Self-injurious skin picking: clinical characteristics and comorbidity. Wilhelm, July 454–459
Upper-extremity self-amputation in a case of dissociative identity disorder [letter]. Brenner; Schlozman reply, Oct 705–706
Serotonin-Norepinephrine Reuptake Inhibitors
SSRIs and SNRIs: broad spectrum of efficacy beyond major depression. Gorman, Suppl 4, 33–38
Sertraline
Early augmentation of sertraline with methylphenidate [letter]. Postolache, Feb 123–124
Penile anesthesia associated with sertraline use [letter]. Deisenhammer, Dec 869–870
Treatment of intermittent explosive disorder with sertraline in 3 patients [letter]. Feder, Mar 195–196
Sexual Behavior
Psychiatric features of 36 men convicted of sexual offenses [CME]. McElroy, June 414–420
Sexual offending and antisocial sexual behavior among patients with schizophrenia. Phillips, Mar 170–175
Sexual Function
Care of the sexually active depressed patient. Hirschfeld, Suppl 17, 32–35
Hyperprolactinemia and male sexual dysfunction [letter]. Dickson, Feb 125
Improved outcome in fluvoxamine-treated patients with SSRI-induced sexual dysfunction [letter]. Banov; Nafziger reply, Dec 866–868
Incidence of sexual dysfunction in healthy volunteers on fluvoxamine therapy. Nafziger, Mar 187–190
Management of sexual side effects of antidepressant therapy. Hirschfeld, Suppl 14, 27–30
Penile anesthesia associated with sertraline use [letter]. Deisenhammer, Dec 870
Relief of SSRI-induced sexual dysfunction with mirtazapine treatment [letter]. Farah, Apr 260–261
Safety of sildenafil for antidepressant-related sexual dysfunction [letter]. Pies; Nurnberg reply, Nov 792
Sildenafil for iatrogenic serotonergic antidepressant medication–induced sexual dysfunction in 4 patients. Nurnberg, Jan 33–35
Sildenafil treatment of antidepressant-induced sexual dysfunction [letter]. Berigan; Ashton reply, Dec 866
Sildenafil treatment of serotonin reuptake inhibitor–induced sexual dysfunction [letter]. Ashton, Mar 194–195
Side Effects see also specific side effects
Adverse reactions of antidepressants in elderly patients. Pollock, Suppl 20, 4–8
Changes in adverse events reported by patients during 6 months of fluoxetine therapy. Zajecka, June 389–394
Critical overview: adverse cutaneous reactions to psychotropic medications. Kimyai-Asadi, Oct 714–725
Methamphetamine-associated obsessional symptoms and effective risperidone treatment: a case report [letter]. Iyo, May 337–338
Some adverse effects of antipsychotics: prevention and treatment. Lader, Suppl 12, 18–21
Signal Transduction
Modulation of CNS signal transduction pathways and gene expression by mood-stabilizing agents: therapeutic implications. Manji, Suppl 2, 27–39
Sildenafil
Safety of sildenafil for antidepressant-related sexual dysfunction [letter]. Pies; Nurnberg reply, Nov 792
Sildenafil for iatrogenic serotonergic antidepressant medication–induced sexual dysfunction in 4 patients. Nurnberg, Jan 33–35
Sildenafil treatment of antidepressant-induced sexual dysfunction [letter]. Berigan; Ashton reply, Dec 866
Sildenafil treatment of serotonin reuptake inhibitor–induced sexual dysfunction [letter]. Ashton, Mar 194–195
Skin Picking
Nosology of compulsive skin-picking [letter]. Stein; Arnold reply, Sept 618–619
Self-injurious skin picking: clinical characteristics and comorbidity. Wilhelm, July 454–459
Sleep
Night terrors, sleepwalking, and confusional arousals in the general population: their frequency and relationship to other sleep and mental disorders [CME]. Ohayon, Apr 268–276
Sleep latency is shortened during 4 weeks of treatment with zaleplon, a novel nonbenzodiazepine hypnotic. Elie, Aug 536–544
Smoking
Development of depression during placebo-controlled trials of bupropion for smoking cessation: case reports. Patten, July 436–441
Social Anxiety Disorder
Cognitive-behavioral therapy for social anxiety disorder: model, methods, and outcome. Otto, Suppl 9, 14–19
Comorbid social anxiety and body dysmorphic disorder: managing the complicated patient. Hollander, Suppl 9, 27–31
Gender differences in the presentation and management of social anxiety disorder. Weinstock, Suppl 9, 9–13
History, epidemiology, and differential diagnosis of social anxiety disorder. Moutier, Suppl 9, 4–8
Introduction. New frontiers in the management of social anxiety disorder: diagnosis, treatment, and clinical course. Pollack, Suppl 9, 3
Social anxiety disorder: designing a pharmacologic treatment strategy. Pollack, Suppl 9, 20–26
Update on the diagnosis and treatment of social anxiety disorder. Liebowitz, Suppl 18, 22–26
Social Phobia
Emergence of social phobia during clozapine treatment and its response to fluoxetine augmentation. Pallanti, Dec 819–823
Nefazodone in social phobia. Van Ameringen, Feb 96–100
Steroids
Lamotrigine as prophylaxis against steroid-induced mania [letter]. Preda, Oct 708–709
Substance Abuse see also Alcohol and Alcoholism; specific substances
Effects of clozapine on aggression and substance abuse in schizophrenic patients. Volavka, Suppl 12, 43–46
History of substance abuse complicates remission from acute mania in bipolar disorder. Goldberg JF, Nov 733–740
Suicide attempts in major affective disorder patients with comorbid substance use disorders. Tondo, Suppl 2, 63–69
Treatment of inhalant abuse with risperidone [letter]. Misra, Sept 620
Suicide
Anticonvulsant therapy and suicide risk in affective disorders. Goodwin, Suppl 2, 89–93
Antidepressants and suicidal risk. Müller-Oerlinghausen, Suppl 2, 94–99
Depression screening as an intervention against suicide. Jacobs, Suppl 2, 42–45
Do antipsychotic medications decrease the risk of suicide in patients with schizophrenia? Palmer, Suppl 2, 100–103
Effects of lithium treatment and its discontinuation on suicidal behavior in bipolar manic-depressive disorders. Baldessarini, Suppl 2, 77–84
Electroconvulsive therapy and suicide risk. Prudic, Suppl 2, 104–110
Expression of the myristoylated alanine-rich C kinase substrate (MARCKS) and MARCKS-related protein (MRP) in the prefrontal cortex and hippocampus of suicide victims. McNamara, Suppl 2, 21–26
Genetics of suicide in depression. Roy, Suppl 2, 12–17
Introduction: effects of medical interventions on suicidal behavior [letter]. Jamison, Suppl 2, 4–6
Lithium therapy and suicide risk. Nilsson, Suppl 2, 85–88
Methods of adolescent suicide prevention. Shaffer, Suppl 2, 70–74
Neurobiology of suicide risk: a review for the clinician. Mann, Suppl 2, 7–11
Relationship between antidepressant treatment and suicide [letter]. Rich; Praschak-Rieder reply, May 340
Risk of suicide in patients with bipolar disorders. Simpson SG, Suppl 2, 53–56
Suicide and schizophrenia: clozapine and the InterSePT study. Meltzer HY, Suppl 12, 47–50
Suicide, assisted suicide, and medical illness. Hendin, Suppl 2, 46–50
Suicide attempts in major affective disorder patients with comorbid substance use disorders. Tondo, Suppl 2, 63–69
Suicide risk in patients with major depressive disorder. Angst, Suppl 2, 57–62
Suicide victims with schizophrenia in different treatment phases and adequacy of antipsychotic medication [CME]. Heilä, Mar 200–208
Summary and conclusions: effects of medical interventions on suicidal behavior. Baldessarini, Suppl 2, 117–122
Texas
Medication treatment for the severely and persistently mentally ill: the Texas Medication Algorithm Project. Rush, May 284–291
Mental health care from the public perspective: the Texas Medication Algorithm Project. Shon, Suppl 3, 16–20
New vs. old antipsychotics: the Texas experience. Reid, Suppl 1, 23–25
Texas Medication Algorithm Project: report of the Texas Consensus Conference Panel on Medication Treatment of Major Depressive Disorder. Crismon, Mar 142–156
Texas Medication Algorithm Project (TMAP) schizophrenia algorithms. Miller, Oct 649–657
Tiagabine
Tiagabine appears not to be efficacious in the treatment of acute mania. Grunze, Nov 759–762
Tourette's Disorder
Reserpine treatment of comorbid Tourette's disorder and tardive dystonia [letter]. Rojas, Oct 709–710
Tramadol
Treatment of restless legs syndrome with tramadol: an open study. Lauerma, Apr 241–244

Transcranial Magnetic Stimulation
Safety and feasibility of repetitive transcranial magnetic stimulation in the treatment of anxious depression in pregnancy: a case report. Nahas, Jan 50–52
Treatment Resistance
Evolving definition of treatment resistance. Peuskens, Suppl 12, 4–8
Tricyclic Antidepressants see also specific drugs
Efficacy of SSRIs and newer antidepressants in severe depression: comparison with TCAs. Hirschfeld, May 326–335
Triglyceride
Olanzapine increases weight and serum triglyceride levels. Osser, Nov 767–770
Tyramine
Refining the MAOI diet: tyramine content of pizzas and soy products. Shulman, Mar 191–193
Valproate
Adverse effect profile and efficacy of divalproex sodium compared to valproic acid: a pharmacoepidemiology study. Zarate, Apr 232–236
Efficacy of lithium vs. valproate in the treatment of mania in the elderly: a retrospective study. Chen, Mar 181–186
Modulation of CNS signal transduction pathways and gene expression by mood-stabilizing agents: therapeutic implications. Manji, Suppl 2, 27–39
Safety and tolerability of oral loading divalproex sodium in acutely manic bipolar patients. Hirschfeld, Dec 815–818
Valproate-induced hyperammonemia in the psychiatric setting: 2 cases [letter]. Panikkar, Aug 557–559
Valproic Acid see Valproate
Venlafaxine
Comparing the efficacy and safety of fluoxetine and venlafaxine in outpatient depression [letter]. Michelson; Costa e Silva reply, May 338–340
Effects of venlafaxine on social activity level in depressed outpatients. Lenderking, Mar 157–163
Efficacy, safety, and tolerability of venlafaxine extended release and buspirone in outpatients with generalized anxiety disorder. Davidson, Aug 528–535
Once-daily venlafaxine extended release (XR) compared with fluoxetine in outpatients with depression and anxiety [letter]. Silverstone, Jan 22–28
Once-daily venlafaxine XR compared with fluoxetine in outpatients with depression and anxiety [letter]. Judge; Silverstone reply, Nov 795–796
Venlafaxine extended release (XR) in the treatment of generalized anxiety disorder. Sheehan, Suppl 22, 23–28
Venlafaxine in the treatment of dysthymia: an open-label study. Hellerstein, Dec 845–849
Venlafaxine versus fluoxetine [letter]. Paton, Oct 708
Vision
Visual field "shimmering" associated with nefazodone [letter]. Greenberg WM, Feb 124
War
Response to missile attacks on civilian targets in patients with panic disorder. Sasson, June 385–388
Weight
Anetholtrithion stabilizes body weight fluctuation caused by excessive water drinking in a patient with schizophrenia: a case report [letter]. Matsuo, Oct 706
Different influences of classical antipsychotics and clozapine on glucose-insulin homeostasis in patients with schizophrenia or related psychoses. Melkersson, Nov 783–791
Distribution of body mass index among individuals with and without schizophrenia. Allison, Apr 215–220
Introduction. Weight gain with psychotropics: size does matter. Masand, Suppl 21, 3–4
Nonpharmacologic and pharmacologic management of weight gain. Greenberg I, Suppl 21, 31–36
Novel antipsychotics: comparison of weight gain liabilities. Wirshing, June 358–363
Olanzapine increases weight and serum triglyceride levels. Osser, Nov 767–770
Physical and psychological consequences of weight gain. Kawachi, Suppl 21, 5–9
Relative weight gain among antipsychotics [letter]. Masand; Stahl reply, Oct 706–708
Weight gain and antipsychotic medications [letter]. Aquila; Masand reply, May 336–337
Weight gain associated with antipsychotic drugs. Ganguli, Suppl 21, 20–24
Weight gain associated with use of psychotropic medications. Sachs, Suppl 21, 16–19
Wisconsin Quality of Life Index
Wisconsin Quality of Life Index: a multidimensional model for measuring quality of life. Diamond, Suppl 3, 29–31
Withdrawal see Drug Discontinuation
Women
Antidepressant treatment of depression in HIV-seropositive women. Ferrando, Nov 741–746
Fertility and reproduction in women with anorexia nervosa: a controlled study [CME]. Bulik, Feb 130–135
Obsessions and compulsions in women with postpartum depression. Wisner, Mar 176–180
Zaleplon
Sleep latency is shortened during 4 weeks of treatment with zaleplon, a novel nonbenzodiazepine hypnotic. Elie, Aug 536–544
Zolpidem
Zolpidem for persistent insomnia in SSRI-treated depressed patients. Asnis, Oct 668–676

Journal of Clinical Psychiatry

Author Index to Volume 60: January 1999 Through December 1999

Abbott JL see Targum SD
Ades J see Lejoyeux M
Ağargün MY see Çetin M
Agid O, Lerer B. Risperidone augmentation of paroxetine in a case of severe, treatment-refractory obsessive-compulsive disorder without comorbid psychopathology [letter]. Jan 55–56
Akiskal HS see Haykal RF
Aksu M see Gönül AS
Ali SO see Goldstein TR
Allen MH see Hirschfeld RMA
Allevi L see Perna G
Allison DB, Fontaine KR, Heo M, Mentore JL, Cappelleri JC, Chandler LP, Weiden PJ, Cheskin LJ. Distribution of body mass index among individuals with and without schizophrenia. Apr 215–220
Alpert JE see Nierenberg AA; Sonawalla SB
Alphs LD, Anand R. Clozapine: the commitment to patient safety. Suppl 12, 39–42
Altemus M, Greenberg BD, Keuler D, Jacobson KR, Murphy DL. Open trial of flutamide for treatment of obsessive-compulsive disorder. July 442–445
Altshuler KZ see Rush AJ
Altshuler LL see Chen ST; Kleiner J
Amann B see Grunze H
Amsterdam JD see Zajecka J
Anand R see Alphs LD
Ananth J, Kenan J. Tardive dyskinesia associated with olanzapine monotherapy [letter]. Dec 870
Ananth J see Swartz JR
Andersen SW see Tollefson GD
Andrade C. Reply to Mahendran R: Obsessive-compulsive symptoms with risperidone [letter]. Apr 261–262
Andrade NN. Review of Stotland NL: *Abortion Facts and Feelings: A Handbook for Women and the People Who Care About Them.* Sept 622
Andreasen NC see Ho B-C
Andrews AM see Murphy DL
Angst F see Angst J
Angst J. Major depression in 1998: are we providing optimal therapy? Suppl 6, 5–9
Angst J, Angst F, Stassen HH. Suicide risk in patients with major depressive disorder. Suppl 2, 57–62
Aquila R, Emanuel M. Weight gain and antipsychotic medications [letter with reply]. May 336–337
Aquila R, Weiden PJ, Emanuel M. Compliance and the rehabilitation alliance. Suppl 19, 23–29
Arai Y see Swartz JR
Arango V see Mann JJ
Arnaud-Castiglioni R see Versiani M
Arnold LM, McElroy SL. Reply to Stein DJ: Nosology of compulsive skin picking [letter]. Sept 618–619
Aromin R see Postolache TT
Aronowitz BR see Hollander E
Arvanitis LA see McManus DQ
Ascher JA see Calabrese JR
Ashton AK. Reply to Berigan TR: Sildenafil treatment of antidepressant-induced sexual dysfunction [letter]. Dec 866
Ashton AK, Bennett RG. Sildenafil treatment of serotonin reuptake inhibitor–induced sexual dysfunction [letter]. Mar 194–195
Asnis GM, Chakraburtty A, DuBoff EA, Krystal A, Londborg PD, Rosenberg R, Roth-Schechter B, Scharf MB, Walsh JK. Zolpidem for persistent insomnia in SSRI-treated depressed patients. Oct 668–676
Asnis J, Faisal A, Sanderson W. Environmental factors in panic disorder [letter]. Apr 264
Awad AG, Voruganti LP. Cost-utility analysis in schizophrenia. Suppl 3, 22–26
Bachofen M, Nakagawa A, Marks IM, Park J-M, Greist JH, Baer L, Wenzel KW, Parkin JR, Dottl SL. Home self-assessment and self-treatment of obsessive-compulsive disorder using a manual and a computer-conducted telephone interview: replication of a U.K.-U.S. study. Aug 545–549
Baer L see Bachofen L; Wilhelm S
Baird JW. Utility of quetiapine in a patient with a history of poor response to previous treatment. Suppl 23, 15
Baker RW see Chengappa KR
Bakish D. Patient with comorbid depression and anxiety: the unmet need. Suppl 6, 20–24
Bakker A, van Dyck R, Spinhoven P, van Balkom AJLM. Paroxetine, clomipramine, and cognitive therapy in the treatment of panic disorder. Dec 831–838
Baldessarini RJ, Jamison KR. Summary and conclusions: effects of medical interventions on suicidal behavior. Suppl 2, 117–122
Baldessarini RJ, Tondo L, Hennen J. Effects of lithium treatment and its discontinuation on suicidal behavior in bipolar manic-depressive disorders. Suppl 2, 77–84
Baldessarini RJ see Jamison KR; Tondo L
Ballenger JC. Clinical guidelines for establishing remission in patients with depression and anxiety. Suppl 22, 29–34
Ballenger JC. Introduction: focus on primary care management of depression. Suppl 7, 3
Ballenger JC, Davidson JRT, Lecrubier Y, Nutt DJ (International Consensus Group on Depression and Anxiety); Goldberg D, Magruder KM, Schulberg HC, Tylee A, Wittchen H-U. Consensus statement on the primary care management of depression from the International Consensus Group on Depression and Anxiety. Suppl 7, 54–61
Ballenger JC see Emmanuel NP; Greenberg PE
Banov MD. Improved outcome in fluvoxamine-treated patients with SSRI-induced sexual dysfunction [letter with reply]. Dec 866–867
Bartelli M see Faravelli C
Bartko JJ see Love RC
Batchelder S see Hellerstein DJ
Bates KS see Rothschild AJ
Battista H-J see Kurzthaler I
Bauer MS, Callahan AM, Jampala C, Petty F, Sajatovic M, Schaefer V, Wittlin B, Powell BJ. Clinical practice guidelines for bipolar disorder from the Department of Veterans Affairs. Jan 9–21; Correction, May 341
Beasley CM Jr see Zajecka J
Bebchuk JM see Manji HK
Becker M see Diamond R
Beckman DA see McElroy SL
Behrens G see Maloney M
Bellodi L see Perna G
Belsare G see Black DW
Benatov R see Reznik I
Bennett RG see Ashton AK
Bensasi S see Mulsant BH
Benvenuti P see Faravelli C
Bergam K see Elliott AJ
Berghöfer A see Müller-Oerlinghausen B
Berigan TR. Sildenafil treatment of antidepressant-induced sexual dysfunction [letter with reply]. Dec 866
Berisford MA see Wirshing DA
Berman RM, Charney DS. Models of antidepressant action. Suppl 14, 16–20
Berndt ER see Greenberg PE
Bernet W. Review of Coffey E (ed): *Textbook of Pediatric Neuropsychiatry.* July 490
Bertino JS Jr see Nafziger AN
Biggs MM see Rush AJ
Black DW, Belsare G, Schlosser S. Clinical features, psychiatric comorbidity, and health-related quality of life in persons reporting compulsive computer use behavior. Dec 839–844
Blackburn GL see Greenberg I
Boehm KE see Carroll NB
Boehringer KL see Rothschild AJ
Böhme R see Bohus MJ
Bohning DE see Nahas Z
Bohus MJ, Landwehrmeyer GB, Stiglmayr CE, Limberger MF, Böhme R, Schmahl CG. Naltrexone in the treatment of dissociative symptoms in patients with borderline personality disorder: open-label trial. Sept 598–603
Borden EK see Mittmann N
Bork JA, Rogers T, Wedlund PJ, de Leon J. Pilot study on risperidone metabolism: the role of cytochromes P450 2D6 and 3A. July 469–476
Bostwick JM, Jaffee MS. Buspirone as an antidote to SSRI-induced bruxism in 4 cases. Dec 857–860

Bowden CL. Introduction: use of mood stabilizers in the treatment of psychiatric disorders. Suppl 5, 3–4
Bowden CL see Calabrese JR
Bowers MB Jr see Preda A
Branch RA see Coley KC
Brar JS see Chengappa KR
Brawman-Mintzer O see Emmanuel NP
Brecher M see Katz IR; Kumar V
Brenner I. Upper-extremity self-amputation in a case of dissociative identity disorder [letter with reply]. Oct 705
Brismar KE see Melkersson KI
Brown R see Shaw M
Brusman LA see McElroy SL
Bryan AL see Goldstein TR
Buckley PF. New antipsychotic agents: emerging clinical profiles. Suppl 1, 12–17
Buckley PF. Role of typical and atypical antipsychotic medications in the management of agitation and aggression. Suppl 10, 52–60
Buckman RW, Malan RD. Clozapine for refractory schizophrenia: the Illinois experience. Suppl 1, 18–22
Bulik CM, Sullivan PF, Fear JL, Pickering A, Dawn A, McCullin M. Fertility and reproduction in women with anorexia nervosa: a controlled study [CME]. Feb 130–135
Bulow K. Management of psychosis and agitation in elderly patients: a primary care perspective. Suppl 13, 22–25
Burgoyne KS see Swartz JR
Bussi R see Perna G
Busto UE see Mittmann N
Butters MA see Nebes RD
Buysse DJ see Nowell PD
Byrne SE see Rothschild AJ
Bystrisky A see Roy-Byrne PP
Cabras PL, Hardoy MJ, Hardoy MC, Carta MG. Clinical experience with gabapentin in patients with bipolar or schizoaffective disorder: results of an open-label study. Apr 245–248
Cahn CH. Review of Shorter E: *History of Psychiatry: From the Era of the Asylum to the Age of Prozac.* Feb 127
Calabrese JR, Bowden CL, Sachs GS, Ascher JA, Monaghan E, Rudd GD, for the Lamictal 602 Study Group. Double-blind, placebo-controlled study of lamotrigine monotherapy in outpatients with bipolar I depression. Feb 79–88
Calabrese JR, Rapport DJ. Mood stabilizers and the evolution of maintenance study designs in bipolar I disorder. Suppl 5, 5–13
Callahan AM see Bauer MS
Cameron S see Coley KC
Cappelleri JC see Allison DB
Carleborg L see Öhman R
Carpenter LL, Jocic Z, Hall JM, Rasmussen SA, Price LH. Mirtazapine augmentation in the treatment of refractory depression. Jan 45–49
Carroll NB, Boehm KE, Strickland RT. Chorea and tardive dyskinesia in a patient taking risperidone [letter]. July 485–487
Carta MG see Cabras PL
Carter CS see Coley KC
Cassic KS see Winsberg ME
Çetin M, Ebrinc S, Ağargün MY, Yiğit S. Risperidone for the treatment of monosymptomatic hypochondriacal psychosis [letter]. Aug 554
Chakraburtty A see Asnis GM
Chambers RA, Druss BG. Droperidol: efficacy and side effects in psychiatric emergencies. Oct 664–667
Chan S see Greenberg I
Chandler LP see Allison DB
Chang W-H see Lane H-Y
Chang Y-C see Lane H-Y
Charney DS see Berman RM
Chatterjee CR, Ringold A. Case report of reduction in alcohol craving and protection against alcohol withdrawal by gabapentin. Sept 617
Chen G see Manji HK
Chen ST, Altshuler LL, Melnyk KA, Erhart SM, Miller E, Mintz J. Efficacy of lithium vs. valproate in the treatment of mania in the elderly: a retrospective study. Mar 181–186
Chengappa KNR, Ebeling T, Kang JS, Levine J, Parepally H. Clozapine reduces severe self-mutilation and aggression in psychotic patients with borderline personality disorder. July 477–484
Chengappa KNR, Sheth S, Brar JS, Parepally H, Marcus S, Gopalani A, Palmer A, Baker RW, Schooler NR. Risperidone use at a state hospital: a clinical audit 2 years after the first wave of risperidone prescriptions. June 373–378
Cheong A see Chong S-A
Cheskin LJ see Allison DB
Chiles JA see Miller AL; Rush AJ
Chiles JK see Miller AL
Chong S-A, Cheong A. Deliberate self-poisoning following fluvoxamine-neuroleptics combination [letter]. Dec 869
Chong S-A, Remington G, Tan C-N. Risperidone treatment of tardive dyskinesia and dystonia [letter]. May 340–341
Ciraulo DA. Review of Carvey PM: *Drug Action in the Central Nervous System.* Dec 871
Claypoole K see Elliott AJ
Clyde C see Katz IR
Cohen LJ. Role of neuropsychiatric pharmacists. Suppl 19, 54–58
Coley KC, Carter CS, DaPos SV, Maxwell R, Wilson JW, Branch RA. Effectiveness of antipsychotic therapy in a naturalistic setting: a comparison between risperidone, perphenazine, and haloperidol. Dec 850–856
Comas-Díaz L see Jacobsen FM
Comtois KA, Cowley DS, Dunner DL, Roy-Byrne PP. Relationship between borderline personality disorder and Axis I diagnosis in severity of depression and anxiety. Nov 752–758
Conley RR see Love RC
Conner KM see Davidson JR
Cooke C, de Leon J. Adding other antipsychotics to clozapine [letter]. Oct 710
Costa e Silva J. Reply to Michelson D: Comparing the efficacy and safety of fluoxetine and venlafaxine in outpatient depression [letter]. May 339–340
Cott A see Wisner KL
Cowley DS see Comtois KA
Cox C see Tariot PN
Craft L see Shaffer D
Craske MG see Roy-Byrne PP
Crismon ML, Trivedi M, Pigott TA, Rush AJ, Hirschfeld RMA, Kahn DA, DeBattista C, Nelson JC, Nierenberg AA, Sackeim HA, Thase ME, and the Texas Consensus Conference Panel on Medication Treatment of Major Depressive Disorder. Texas Medication Algorithm Project: report of the Texas Consensus Conference Panel on Medication Treatment of Major Depressive Disorder. Mar 142–156
Crismon ML see Miller AL; Rush AJ; Shon SP
Croghan IT see Patten CA
Cummings JL see Ringman JM
Cyrus PA see Raskind MA
DaPos SV see Coley KC
David D, Kutcher GS, Jackson EI, Mellman TA. Psychotic symptoms in combat-related posttraumatic stress disorder. Jan 29–32
David D, Mellman TA. Reply to Pies R: Defining psychosis in PTSD [letter]. Aug 555–556
David K see Mauskopf JA
Davidson JRT, Conner KM. Management of posttraumatic stress disorder: diagnostic and therapeutic issues. Suppl 18, 33–38
Davidson JRT, DuPont RL, Hedges D, Haskins JT. Efficacy, safety, and tolerability of venlafaxine extended release and buspirone in outpatients with generalized anxiety disorder. Aug 528–535
Davidson JRT, Meltzer-Brody SE. Underrecognition and undertreatment of depression: what is the breadth and depth of the problem? Suppl 7, 4–9
Davidson JRT see Ballenger JC; Foa EB; Greenberg PE
Davies RK see Rojas VM
Dawn A see Bulik CM
DeAntonio M see Strober M
DeBattista C see Crismon ML; Schatzberg AF
Deckersbach T see Wilhelm S
de Haan L, Linszen DH, Gorsira R. Clozapine and obsessions in patients with recent-onset schizophrenia and other psychotic disorders. June 364–365
Deisenhammer EA, Trawöger R. Penile anesthesia associated with sertraline use [letter]. Dec 869–870
de Leon J see Bork JA; Cooke C
DeMarco LM see Eisen JL
de Moore GM see Ferrando SJ
Denicoff KD see Goldstein TR
DeQuardo JR. Reply to McGorry PD: Recommended haloperidol and risperidone doses in first-episode psychosis [letter]. Nov 794–795
Dernovsek MZ see Tavcar R
Deutch AY. Review of Bear MF, Connors BW, Paradisio MA: *Neuroscience: Exploring the Brain.* Jan 59
DeVane CL, Pollock BG. Pharmacokinetic considerations of antidepressant use in the elderly. Suppl 20, 38–44
DeVane CL see Goodnick PJ
Dew MA see Nowell PD
Diamond R, Becker M. Wisconsin Quality of Life Index: a multidimensional model for measuring quality of life. Suppl 3, 29–31
Di Bernardo M see Faravelli C
Dickson RA, Glazer WM. Hyperprolactinemia and male sexual dysfunction [letter]. Feb 125
Dieperink BS. Review of Stern TA, Herman JB, Slavin PL (eds): *MGH Guide to Psychiatry in Primary Care.* Feb 128
Docherty JP. Cost of treating mental illness from a managed care perspective. Suppl 3, 49–52
Dodge MR, Goldberg TE. Associations between cognitive impairment and tardive dyskinesia: another perspective. Suppl 13, 17–21
Donoghue J see Haddad P

Dottl SL see Bachofen L
Druss BG see Chambers RA
DuBoff EA see Asnis GM
Dufresne RL see Osser DN
Dulisse BK see Tunis SL
Dunner DL see Comtois KA
DuPont RL see Davidson JRT
Ebeling T see Chengappa KNR
Ebrinc S see Çetin M
Eisen JL, Goodman WK, Keller MB, Warshaw MG, DeMarco LM, Luce DD, Rasmussen SA. Patterns of remission and relapse in obsessive-compulsive disorder: a 2-year prospective study [CME]. May 346–351
Eisenstein N see Howanitz E
Elia J see Weller EB
Elie R, Rüther E, Farr I, Emilien G, Salinas E, for the Zaleplon Clinical Study Group. Sleep latency is shortened during 4 weeks of treatment with zaleplon, a novel nonbenzodiazepine hypnotic. Aug 536–544
Elliott AJ, Russo J, Bergam K, Claypoole K, Uldall KK, Roy-Byrne PP. Antidepressant efficacy in HIV-seropositive outpatients with major depressive disorder: an open trial of nefazodone. Apr 226–231
El-Mallakh RS. Rapid fade of antidepressant effect of nefazodone in bipolar depression [letter]. Aug 559
El-Mallakh RS, Waltrip C, Peters. Can long-term antidepressant use be depressogenic? [letter with reply] Apr 263
Emanuel M see Aquila R
Emilien G see Elie R
Emmanuel NP, Ware MR, Brawman-Mintzer O, Ballenger JC, Lydiard RB. Once-weekly dosing of fluoxetine in the maintenance of remission in panic disorder. May 299–301
Emsley RA. Partial response to antipsychotic treatment: the patient with enduring symptoms. Suppl 23, 10–11
Emsley RA, Oosthuizen PP, Joubert AF, Roberts MC, Stein DJ. Depressive and anxiety symptoms in patients with schizophrenia and schizophreniform disorder. Nov 747–751
Engelhard IM see Wilhelm S
Engelhart C see Howanitz E
Engelhart L see Mahmoud R
Epperson CN see Weiss EL
Erb R see Tariot PN
Ereshefsky L. Pharmacologic and pharmacokinetic considerations in choosing an antipsychotic. Suppl 10, 20–30
Erfurth A see Grunze H
Erhart SM see Chen ST
Evans DL. Introduction: assessing antidepressant efficacy. Suppl 4, 3
Evans DL, Staab JP, Petitto JM, Morrison MF, Szuba MP, Ward HE, Wingate B, Luber MP, O'Reardon JP. Depression in the medical setting: biopsychological interactions and treatment considerations. Suppl 4, 40–55
Evans JD, Heaton RK, Paulsen JS, McAdams LA, Heaton SC, Jeste DV. Schizoaffective disorder: a form of schizophrenia or affective disorder? [CME] Dec 874–882
Faisal A see Asnis J
Falkai P. Mirtazapine: other indications. Suppl 17, 36–40
Farah A. Relief of SSRI-induced sexual dysfunction with mirtazapine treatment [letter]. Apr 260–261
Faravelli C, Di Bernardo M, Ricca V, Benvenuti P, Bartelli M, Ronchi O. Effects of chronic lithium treatment on the peripheral nervous system. May 306–310
Farmer RG. Review of Yehuda R (ed): *Psychological Trauma (Review of Psychiatry Series, Vol. 17).* Oct 712
Farr I see Elie R
Farren CK see Namkoong K
Fava M, Rosenbaum JF. Anger attacks in patients with depression. Suppl 15, 21–24
Fava M see Nierenberg AA; Sonawalla SB
Fazeli A see Preda A
Fear JL see Bulik CM
Fedak MJ see Hellerstein DJ
Feder R. Treatment of intermittent explosive disorder with sertraline in 3 patients. Mar 195–196
Feighner JP. Mechanism of action of antidepressant medications. Suppl 4, 4–11
Feighner JP. Overview of antidepressants currently used to treat anxiety disorders. Suppl 22, 18–22
Feighner JP, Overø K. Multicenter, placebo-controlled, fixed-dose study of citalopram in moderate to severe depression. Dec 824–830
Ferrando SJ, Rabkin JG, de Moore GM, Rabkin R. Antidepressant treatment of depression in HIV-seropositive women. Nov 741–746
Ferrier IN. Treatment of major depression: is improvement enough? Suppl 6, 10–14
Feuche N see Lejoyeux M
Finkelstein SN see Greenberg PE
Fitzgerald RG. Review of Gabbard GO, Gabbard K: *Psychiatry and the Cinema, 2nd ed.* Oct 712
Fitzgerald WL Jr. Legal and ethical considerations in the treatment of psychosis. Suppl 19, 59–65
Fleischhacker WW. Clozapine: a comparison with other novel antipsychotics. Suppl 12, 30–34
Fleischhacker WW see Kurzthaler I
Foa EB, Davidson JRT, Frances A (eds). Treatment of Posttraumatic Stress Disorder [Expert Consensus Guideline Series]. Suppl 16, 1–76
Fontaine KR see Allison DB
Forker AE see Wilhelm S
Frances A see Foa EB; McEvoy JP
Franchini L, Zanardi R, Gasperini M, Smeraldi E. Two-year maintenance treatment with citalopram, 20 mg, in unipolar subjects with high recurrence rate. Dec 861–865
Franz MA see Sobel M
Freed M. Review of Goldberg JF, Harrow M (eds): *Bipolar Disorders: Clinical Course and Outcome.* Nov 797
Freeman AM. Review of Murray R, Hill P, McGuffin P (eds): *The Essentials of Postgraduate Psychiatry, 3rd ed.* May 342–343
Freeman EB Sr. Symptom relief and improved social functioning following treatment with quetiapine in a schizophrenic patient with a history of poor response to antipsychotics. Suppl 23, 12
Freeman R see Strober M
Freund B see Goodnick PJ
Frye MA see Goldstein TR
Fuchs DC. Review of Barkley RA, Murphy KR (eds): *Attention-Deficit Hyperactivity Disorder: A Clinical Workbook, 2nd ed.* Feb 127–128
Fuchs DC. Review of The Committee on Child Psychiatry for GAP: *In the Long Run: Longitudinal Studies of Psychopathology in Children (GAP Report No. 143).* Aug 560
Fuller W see Misra LK
Fux M see Sasson Y
Fyer AJ see Greenberg PE
Gadasally R see Swartz JR
Ganguli M see Mulsant BH
Ganguli R. Weight gain associated with antipsychotic drugs. Suppl 21, 20–24
Garno JL see Goldberg JF
Garside S, Rosebush PI, Levinson AJ, Mazurek MF. Late-onset adrenoleukodystrophy associated with long-standing psychiatric symptoms. July 460–468
Gasperini M see Franchini L
Gaszner P see Versiani M
Gaynes BN see McLeod MN
Gelenberg AJ. Annual gratitude. Feb 74–76
Gelenberg AJ. Millennial musings [editorial]. Nov 730
Gelenberg AJ. Reply to Mandelkern M: Manufacturer support and outcome [letter]. Feb 122–123
George MS see Nahas Z
Gerlach J. Conclusions. Learning from our patients: key issues in the clinical treatment of schizophrenia from a longitudinal perspective. Suppl 23, 34
Gerlach J. Continuing problem of extrapyramidal symptoms: strategies for avoidance and effective treatment. Suppl 23, 20
Gerlach J. Introduction. Learning from our patients: key issues in the clinical treatment of schizophrenia from a longitudinal perspective. Suppl 23, 3–4
Ghiani C see Tondo L
Gibson PJ see Mauskopf JA; Tunis SL
Gigliotti T see Wisner KL
Gillin JC. Review of Hartmann E: *Dreams and Nightmares: The New Theory on the Origin and Meaning of Dreams.* Apr 265–266
Gilman SM see Panikkar GP
Glazer WM. Does loxapine have "atypical" properties? clinical evidence. Suppl 10, 42–46
Glazer WM. Reply to Sheeley WF: Capitation [letter]. Jan 54–55
Glazer WM see Dickson RA
Glick ID see Schulz SC
Glitz D see Manji HK
Goldberg D. Management of anxious depression in primary care. Suppl 7, 39–42
Goldberg D see Ballenger JC
Goldberg JF, Garno JL, Leon AC, Kocsis JH, Portera L. A history of substance abuse complicates remission from acute mania in bipolar disorder. Nov 733–740
Goldberg TE see Dodge MR
Golden RN see McLeod MN
Goldman LS. Medical illness in patients with schizophrenia. Suppl 21, 10–15
Goldstein D see Wirshing DA
Goldstein TR, Frye MA, Denicoff KD, Smith-Jackson E, Leverich GS, Bryan AL, Ali SO, Post RM. Antidepressant discontinuation–related mania: critical prospective observation and theoretical implications in bipolar disorder [CME]. Aug 563–567
Gönül AS, Aksu M. SSRI-induced parkinsonism may be an earlier sign of future Parkinson's disease [letter]. June 410
Goodman WK. Obsessive-compulsive disorder: diagnosis and treatment. Suppl 18, 27–32
Goodman WK see Eisen JL

Goodnick PJ, Puig A, DeVane CL, Freund B. Mirtazapine in major depression with comorbid generalized anxiety disorder. July 446–448
Goodwin FK. Anticonvulsant therapy and suicide risk in affective disorders. Suppl 2, 89–93
Gopalani A see Chengappa KR
Gorfinkle KS see Simpson HB
Gorman JM. Mirtazapine: clinical overview. Suppl 17, 9–13
Gorman JM, Kent JM. SSRIs and SNRIs: broad spectrum of efficacy beyond major depression. Suppl 4, 33–38
Gorsira R see de Haan L
Goss-Bley AI see Nafziger AN
Grainger DL see Mauskopf JA
Green B. Quetiapine in the management of treatment-emergent tardive dyskinesia and parkinsonian side effects: a case report. Suppl 23, 21–22
Greenberg BD see Altemus M
Greenberg I, Chan S, Blackburn GL. Nonpharmacologic and pharmacologic management of weight gain. Suppl 21, 31–36
Greenberg PE, Sisitsky T, Kessler RC, Finkelstein SN, Berndt ER, Davidson JRT, Ballenger JC, Fyer AJ. Economic burden of anxiety disorders in the 1990s. July 427–435
Greenberg WM. Visual field "shimmering" associated with nefazodone [letter]. Feb 124
Greene YM, Noviasky J, Tariot PN. Donepezil overdose [letter]. Jan 56–57
Greeno CG see Mammen OK
Greist JH see Bachofen M
Gross R see Sasson Y
Grundy S see Tohen M
Grunze H, Erfurth A, Marcuse A, Amann B, Normann C, Walden J. Tiagabine appears not to be efficacious in the treatment of acute mania. Nov 759–762
Guille C see Sachs GS
Guilleminault C see Ohayon MM
Gulanski BI see Raskind MA
Günther V see Kurzthaler I
Haddad P, Donoghue J. Pharmacists lack knowledge of antidepressant discontinuation symptoms [letter with reply]. Feb 124–125
Hägg S see Öhman R
Hale MS see Lenderking WR
Hall JM see Carpenter LL
Hanson MA. Introduction: pharmacoeconomics of treatment-resistant schizophrenia. Suppl 1, 3
Hanson MA. Pharmacoeconomics of schizophrenia in the 21st century. Suppl 1, 26–27
Hanusa BH see Wisner KL
Hardoy MC see Cabras PL
Hardoy MJ see Cabras PL
Harris JC see Kimyai-Asadi A
Harris MJ see Lindamer LA
Hart DA. Patient's coping skills and environmental stress important to understanding recurrence during antidepressant maintenance [letter]. Aug 556
Harvey PD. Cognitive functioning in late-life schizophrenia: its importance and implications for overall outcome. Suppl 13, 10–16
Hasanat KA see Manji HK
Haskins JT see Davidson JRT
Haykal RF, Akiskal HS. Long-term outcome of dysthymia in private practice: clinical features, temperament, and the art of management. Aug 508–518
Hays JT see Patten CA
Heads TC see Phillips SL
Heaton RK see Evans JD
Heaton SC see Evans JD
Hedges D see Davidson JRT
Heikkinen ME see Heilä H
Heilä H, Isometsä ET, Henriksson MM, Heikkinen ME, Marttunen MJ, Lönnqvist JK. Suicide victims with schizophrenia in different treatment phases and adequacy of antipsychotic medication [CME]. Mar 200–208
Hellerstein DJ, Batchelder ST, Little SAS, Fedak MJ, Kreditor D, Rosenthal J. Venlafaxine in the treatment of dysthymia: an open-label study. Dec 845–849
Hellerstein DJ see Postolache TT
Hellewell JSE. Treatment-resistant schizophrenia: reviewing the options and identifying the way forward. Suppl 23, 14
Hendin H. Suicide, assisted suicide, and medical illness. Suppl 2, 46–50
Hendrick V see Kleiner J
Hennen J see Baldessarini RJ; Tondo L
Henriksson MM see Heilä H
Hensley PL see Nurnberg HG
Henter ID see Palmer DD
Heo M see Allison DB
Herrmann N see Mittmann N
Hershman JM see Kleiner J
Hill GM see Phillips SL
Hippius H. Historical perspective of clozapine. Suppl 12, 22–23
Hirschfeld RMA. Care of the sexually active depressed patient. Suppl 17, 32–35
Hirschfeld RMA. Efficacy of SSRIs and newer antidepressants in severe depression: comparison with TCAs. May 326–335
Hirschfeld RMA. Management of sexual side effects of antidepressant therapy. Suppl 14, 27–30
Hirschfeld RMA, Allen MH, McEvoy J, Keck PE Jr, Russell J. Safety and tolerability of oral loading divalproex sodium in acutely manic bipolar patients. Dec 815–818
Hirschfeld RMA see Crismon ML
Ho B-C, Miller D, Nopoulos P, Andreasen NC. Comparative effectiveness study of risperidone and olanzapine in the treatment of schizophrenia. Oct 658–663
Hollander E. Managing aggressive behavior in patients with obsessive-compulsive disorder and borderline personality disorder. Suppl 15, 38–44
Hollander E, Aronowitz BR. Comorbid social anxiety and body dysmorphic disorder: managing the complicated patient. Suppl 9, 27–31
Houck PR see Mulsant BH
Howanitz E, Pardo M, Smelson DA, Engelhart C, Eisenstein N, Stern RG, Losonczy MF. Efficacy and safety of clozapine versus chlorpromazine in geriatric schizophrenia. Jan 41–44; Correction, May 341
Hubbard JR. Review of Marlatt GA (ed): *Harm Reduction: Pragmatic Strategies for Managing High-Risk Behaviors.* June 412
Hulting A-L see Melkersson KI
Hummer M see Kurzthaler I
Hurt RD see Patten CA
Hwang J-P, Tsai S-J, Yang C-H, Liu K-M, Lirng J-F. Persecutory delusions in dementia. Aug 550–553
Hyde TM see McNamara RK
International Consensus Group on Depression and Anxiety see Ballenger JC
Irvine C see Tariot PN
Isometsä ET see Heilä H
Iyo M, Sekine Y, Matsunaga T, Tsukamoto T, Takei N, Mori N. Methamphetamine-associated obsessional symptoms and effective risperidone treatment: a case report [letter]. May 337–338
Jackson EI see David D
Jacobs DG. Depression screening as an intervention against suicide. Suppl 2, 42–45
Jacobs M see Schulz SC
Jacobsen FM, Comas-Díaz L. Donepezil for psychotropic-induced memory loss. Oct 698–704
Jacobson KR see Altemus M
Jaffee MS see Bostwick JM
Jaggers ED see Sobel M
Jakimovich LJ see Tariot PN
Jamison KR, Baldessarini RJ. Introduction: effects of medical interventions on suicidal behavior. Suppl 2, 4–6
Jamison KR see Baldessarini RJ; Simpson SG
Jampala C see Bauer MS
Jann MW see Lane H-Y
Jayathilake K see Meltzer HY
Jenike MA see Wilhelm S
Jeste DV. Introduction: newer drugs for older patients. Suppl 13, 3–4
Jeste DV see Evans JD; Katz IR; Lindamer LA
Jibson MD see Tandon R
Jocic Z see Carpenter LL
Joffe RT see Levitt AJ
Johnstone BM see Tunis SL
Jones H. Use of quetiapine in first-episode schizophrenia: a case study. Suppl 23, 6–7
Joubert AF see Emsley RA
Judge R, Wagner BE. Once-daily venlafaxine XR compared with fluoxetine in outpatients with depression and anxiety [letter with reply]. Nov 795–796
Juncos JL. Management of psychotic aspects of Parkinson's disease. Suppl 8, 42–53
Kahn DA see Crismon ML
Kales HC, Mellow AM. Ileus as a possible result of bupropion in an elderly woman [letter]. May 337
Kalin NH. Primate models to understand human aggression. Suppl 15, 29–32
Kamil R see Levitt AJ
Kane JM. Management strategies for the treatment of schizophrenia. Suppl 12, 13–17
Kane JM. Tardive dyskinesia in affective disorders. Suppl 5, 43–47
Kang JS see Chengappa KNR
Kapur S see Remington G
Kashner TM see Rush AJ
Kashuba ADM see Nafziger AN
Kasper S. First-episode schizophrenia: the importance of early intervention and subjective tolerability. Suppl 23, 5
Kasper S see Praschak-Rieder N
Katon WJ see Roy-Byrne PP; Schulberg HC
Katz IR, Jeste DV, Mintzer JE, Clyde C, Napolitano J, Brecher M, for the Risperidone Study Group. Comparison of risperidone and placebo for psychosis and behavioral disturbances associated with dementia: a randomized, double-blind trial. Feb 107–115
Kawachi I. Physical and psychological consequences of weight gain. Suppl 21, 5–9
Keck PE Jr see Hirschfeld RMA; McElroy SL
Keefe BR see Nierenberg AA

Keith SJ see Nurnberg HG
Keller MB. Long-term treatment of depression. Suppl 17, 41–45
Keller MB, Pinder RM. Introduction: scientific expert meeting. Suppl 17, 3
Keller MB see Eisen JL
Kelly DL see Love RC
Kelton GM see Postolache TT
Kenan J see Ananth J
Kent JM see Gorman JM
Kent RS. Bupropion clarification [letter]. Mar 196
Kessler RC see Greenberg PE
Keuler D see Altemus M
Keuthen NJ see Wilhelm S
Kim L see Kim Y-K
Kim Y-K, Kim L, Lee M-S. Risperidone and associated amenorrhea: a report of 5 cases. May 315–317
Kimyai-Asadi A, Harris JC, Nousari HC. Critical overview: adverse cutaneous reactions to psychotropic medications [CME]. Oct 714–725
Kleiner J, Altshuler L, Hendrick V, Hershman JM. Lithium-induced subclinical hypothyroidism: review of the literature and guidelines for treatment. Apr 249–255
Kleinman JE see McNamara RK
Kocsis JH see Goldberg JF
Kofoed L see Misra LK
Kolko DJ see Mammen OK
Kolsky AR see Sonawalla SB
Koran LM see Winsberg ME
Kowalcyk BB see McManus DQ
Kozlupa DM. Efficacy of quetiapine in relieving persistent symptoms in a patient with poor response to both conventional and atypical antipsychotic therapy. Suppl 23, 13
Kraus JE. Treatment of kleptomania with paroxetine [letter]. Nov 793
Kreditor D see Hellerstein DJ
Krishnan KR. Brain imaging correlates. Suppl 15, 50–54
Krystal A see Asnis GM
Kumar V, Brecher M. Psychopharmacology of atypical antipsychotics and clinical outcomes in elderly patients. Suppl 13, 5–9
Kuperman S see Quintero CV
Kupfer DJ see Nowell PD
Kurzthaler I, Hummer M, Miller C, Sperner-Unterweger B, Günther V, Wechdorn H, Battista H-J, Fleischhacker WW. Effect of cannabis use on cognitive functions and driving ability. June 395–399
Kutcher GS see David D
Kysar L see Wirshing DA
Lader M. Some adverse effects of antipsychotics: prevention and treatment. Suppl 12, 18–21
Lamictal 602 Study Group see Calabrese JR
Landwehrmeyer GB see Bohus MJ
Lane H-Y, Chang W-H. Clozapine versus risperidone in treatment-refractory schizophrenia: possible impact of dosing strategies [letter]. July 487–488
Lane H-Y, Chang Y-C, Chang W-H, Lin S-K, Tseng Y-T, Jann MW. Effects of gender and age on plasma levels of clozapine and its metabolites: analyzed by critical statistics. Jan 36–40
Lane H-Y, Su K, Chang W-H. Seizures after discontinuation of low-dose lorazepam from originally seizure-free clozapine regimen: combined effects? [letter] June 408–409
Lanning B see Tariot PN
Lauerma H, Markkula J. Treatment of restless legs syndrome with tramadol: an open study. Apr 241–244
Lauriello J see Nurnberg HG
Lecrubier Y see Ballenger JC
Lee KMS. Rapid relief from the symptoms of schizophrenia with quetiapine: a case study. Suppl 23, 8–9
Lee M-S see Kim Y-K
Lehman AF. Developing an outcomes-oriented approach for the treatment of schizophrenia. Suppl 19, 30–37
Lehman AF. Introduction. Antipsychotic agents: clinical, economic, and legal considerations in the treatment of psychosis. Suppl 19, 3–4
Lejoyeux M, Feuche N, Loi S, Solomon J, Ades J. Study of impulse-control disorders among alcohol-dependent patients. May 302–305
Lenderking WR, Tennen H, Nackley JF, Hale MS, Turner RR, Testa MA. Effects of venlafaxine on social activity level in depressed outpatients. Mar 157–163
Lenox RH see McNamara RK
Leon AC see Goldberg JF
Lerer B see Agid O
Leslie VC see Nierenberg AA
Leverich GS see Goldstein TR
Levine J see Chengappa KNR
Levinson AJ see Garside S
Levitt AJ, Joffe RT, Kamil R, McIntyre R. Do depressed subjects who have failed both fluoxetine and a tricyclic respond to the combination? Sept 613–616
Lieb R see Wittchen H-U
Lieberman JA. Pathophysiologic mechanisms in the pathogenesis and clinical course of schizophrenia. Suppl 12, 9–12
Liebowitz MR. Update on the diagnosis and treatment of social anxiety disorder. Suppl 18, 22–26
Liebowitz MR see Simpson HB
Limberger MF see Bohus MJ
Lin S-K see Lane H-Y
Lindamer LA, Lohr JB, Harris MJ, McAdams LA, Jeste DV. Gender-related clinical differences in older patients with schizophrenia [CME]. Jan 61–67
Linszen DH see de Haan L
Lirng J-F see Hwang J-P
Little JT see Mulsant BH
Little SAS see Hellerstein DJ
Liu K-H see Hwang J-P
Lohr JB see Lindamer LA
Loi S see Lejoyeux M
Londborg PD see Asnis GM
Londono JH see Postolache TT
Lönnqvist JK see Heilä H
Loosbrock DL see Tunis SL
Losonczy MF see Howanitz E
Love RC, Conley RR, Kelly DL, Bartko JJ. A dose-outcome analysis of risperidone. Nov 771–775
Luber MP see Evans DL
Luce DD see Eisen JL
Lydiard RB see Emmanuel NP
Macmillan I, Young A. Bipolar II disorder vs. premenstrual dysphoric disorder [letter]. June 409–410
Madrid AR see Zarate CA Jr
Magruder KM, Norquist GS. Structural issues and policy in the primary care management of depression. Suppl 7, 45–51
Magruder KM see Ballenger JC
Mahendran R. Obsessive-compulsive symptoms with risperidone [letter with replies]. Apr 261
Mahmoud R, Engelhart L, Ollendorf D, Oster G. Risperidone Outcomes Study of Effectiveness (ROSE): a model for evaluating treatment strategies in typical psychiatric practice. Suppl 3, 42–47
Maixner SM, Mellow AM, Tandon R. Efficacy, safety, and tolerability of antipsychotics in the elderly. Suppl 8, 29–41
Malan RD see Buckman RW
Maloney M, Behrens G. Review of Mash EJ, Barkley RA (eds): *Treatment of Childhood Disorders, 2nd ed.* June 411–412
Mammen OK, Shear MK, Pilkonis PA, Kolko DJ, Thase ME, Greeno CG. Anger attacks: correlates and significance of an underrecognized symptom. Sept 633–642
Mancini C see Van Ameringen M
Mandelkern M. Manufacturer support and outcome [letter with reply]. Feb 122
Manji HK, Bebchuk JM, Moore GJ, Glitz D, Hasanat KA, Chen G. Modulation of CNS signal transduction pathways and gene expression by mood-stabilizing agents: therapeutic implications. Suppl 2, 27–39
Mann JJ, Oquendo M, Underwood MD, Arango V. Neurobiology of suicide risk: a review for the clinician. Suppl 2, 7–11
Manning WG Jr. Panel on cost-effectiveness in health and medicine recommendations: identifying costs. Suppl 3, 54–56
Mannu P see Tondo L
Marcus S see Chengappa KR
Marcuse A see Grunze H
Marder SR see Wirshing DA
Markkula J see Lauerma H
Markowitz JC. Rap and mania [letter]. Aug 554–555
Marks IM see Bachofen M
Martin PR. Review of Frances RJ, Miller SI (eds): *Clinical Textbook of Addictive Disorders, 2nd ed.* Dec 872
Marttunen MJ see Heilä H
Masand PS. Introduction. Weight gain with psychotropics: size does matter. Suppl 21, 3–4
Masand PS. Relative weight gain among antipsychotics [letter with reply]. Oct 706–708
Masand PS. Reply to Aquila R: Weight gain and antipsychotic medications [letter]. May 336–337
Masia M see Tondo L
Matsunaga T see Iyo M
Matsuo S-I, Ninomiya H, Takasiba T, Sasaki Y. Anetholtrithion stabilizes body weight fluctuation caused by excessive water drinking in a patient with schizophrenia: a case report [letter]. Oct 706
Mattia JI see Zimmerman M
Mauskopf JA, David K, Grainger DL, Gibson PJ. Annual health outcomes and treatment costs for schizophrenia populations. Suppl 19, 14–22
Maxwell R see Coley KC
Mazumdar S see Mulsant BH
Mazure CM see Preda A
Mazurek MF see Garside S
McAdams LA see Evans JD; Lindamer LA
McCombs JS, Nichol MB, Stimmel GL, Shi J, Smith RR. Use patterns for antipsychotic medications in Medicaid patients with schizophrenia. Suppl 19, 5–13
McCullin M see Bulik CM
McDonald J see Zarate CA Jr
McDougle CJ see Weiss EL

McElroy SL. Recognition and treatment of DSM-IV intermittent explosive disorder. Suppl 15, 12–16
McElroy SL, Keck PE Jr, Strakowski SM. Overview of the treatment of schizoaffective disorder. Suppl 5, 16–21
McElroy SL, Soutullo CA, Taylor P Jr, Nelson EB, Beckman DA, Brusman LA, Ombaba JM, Strakowski SM, Keck PE Jr. Psychiatric features of 36 men convicted of sexual offenses [CME]. June 414–420
McElroy SL see Arnold LM
McEvoy JP, Scheifler PL, Frances A (eds). Treatment of Schizophrenia 1999 [Expert Consensus Guideline Series]. Suppl 11, 1–80
McEvoy JP see Hirschfeld RMA
McGorry PD. Recommended haloperidol and risperidone doses in first-episode psychosis [letter with reply]. Nov 794
McGurk SR. Effects of clozapine on cognitive functioning in schizophrenia. Suppl 12, 24–29
McIntyre R see Levitt AJ
McKay BG see Preda A
McLeod MN, Gaynes BN, Golden RN. Chromium potentiation of antidepressant pharmacotherapy for dysthymic disorder in 5 patients. Apr 237–240
McManus DQ, Arvanitis LA, Kowalcyk BB, for the Seroquel Trial 48 Study Group. Quetiapine, a novel antipsychotic: experience in elderly patients with psychotic disorders. May 292–298
McNamara RK, Hyde TM, Kleinman JE, Lenox RH. Expression of the myristoylated alanine-rich C kinase substrate (MARCKS) and MARCKS-related protein (MRP) in the prefrontal cortex and hippocampus of suicide victims. Suppl 2, 21–26
McQuaid J see Roy-Byrne PP
Mehilane L see Versiani M
Melkersson KI, Hulting A-L, Brismar KE. Different influences of classical antipsychotics and clozapine on glucose-insulin homeostasis in patients with schizophrenia or related psychoses. Nov 783–791
Mellman TA see David D
Mellow AM see Kales HC; Maixner SM
Melnyk KA see Chen ST
Meltzer D. Perspective and the measurement of costs and benefits for cost-effectiveness analysis in schizophrenia. Suppl 3, 32–35
Meltzer HY. Outcome in schizophrenia: beyond symptom reduction. Suppl 3, 3–7
Meltzer HY. Review of Nasar S: *Beautiful Mind: A Biography of John Forbes Nash, Jr.* Apr 266
Meltzer HY. Suicide and schizophrenia: clozapine and the InterSePT study. Suppl 12, 47–50
Meltzer HY, Jayathilake K. Low-dose loxapine in the treatment of schizophrenia: is it more effective and more "atypical" than standard-dose loxapine? Suppl 10, 47–51
Meltzer-Brody SE see Davidson JRT
Mentore JL see Allison DB
Mercier E see Roy-Byrne PP
Metrifonate Study Group see Raskind MA
Michelson D. Comparing the efficacy and safety of fluoxetine and venlafaxine in outpatient depression [letter with reply]. May 338–339
Michelson D see Zajecka J
Miller AL, Chiles JA, Chiles JK, Crismon ML, Rush AJ, Shon SP. Texas Medication Algorithm Project (TMAP) schizophrenia algorithms. Oct 649–657
Miller AL see Rush AJ; Shon SP; Velligan DI
Miller C see Kurzthaler I
Miller D see Ho B-C
Miller E see Chen ST
Miller MC. Review of Bremner JD, Marmar CR (eds): *Trauma, Memory, and Dissociation.* Sept 621–622
Miller MC. Review of Ingram RE, Miranda J, Segal ZV: *Cognitive Vulnerability to Depression.* Mar 197–198
Miller MD see Mulsant BH
Milner K see Tandon R
Minnai GP see Tondo L
Mintz J see Chen ST; Wirshing DA
Mintzer JE see Katz IR
Misra LK, Kofoed L, Fuller WC. Treatment of inhalant abuse with risperidone [letter]. Sept 620
Mittmann N, Herrmann N, Shulman KI, Silver IL, Busto UE, Borden EK, Naranjo CA, Shear NH. Effectiveness of antidepressants in elderly depressed outpatients: a prospective case series study. Oct 690–697
Molloy MA see Nahas Z
Monaghan E see Calabrese JR
Montano CB. Primary care issues related to the treatment of depression in elderly patients. Suppl 20, 45–51
Montgomery SA. New developments in the treatment of depression. Suppl 14, 10–15
Moore GJ see Manji HK
Moore RF. Review of Bernstein BE, Hartsell TL Jr: *Portable Lawyer for Mental Health Professionals: A–Z Guide to Protecting Your Clients, Your Practice, and Yourself.* Apr 265
Mori N see Iyo M
Moroz G, Rosenbaum JF. Efficacy, safety, and gradual discontinuation of clonazepam in panic disorder: a placebo-controlled, multicenter study using optimized dosages. Sept 604–612
Morrison MF see Evans DL
Mors O see Nielsen AS
Moutier CY, Stein MB. History, epidemiology, and differential diagnosis of social anxiety disorder. Suppl 9, 4–8
Müller-Oerlinghausen B, Berghöfer A. Antidepressants and suicidal risk. Suppl 2, 94–99
Mulsant BH, Ganguli M. Epidemiology and diagnosis of depression in late life. Suppl 20, 9–15
Mulsant BH, Pollock BG, Nebes RD, Miller MD, Little JT, Stack J, Houck PR, Bensasi S, Mazumdar S, Reynolds CF III. Double-blind randomized comparison of nortriptyline and paroxetine in the treatment of late-life depression: 6-week outcome. Suppl 20, 16–20
Mulsant BH see Nebes RD; Walters G
Muran JC see Postolache TT
Murphy DL see Altemus M
Musa MN. Paroxetine for primary insomnia: possible placebo effect? [letter] Nov 795
Naber D. Optimizing clozapine treatment. Suppl 12, 35–38
Nackley JF see Lenderking WR
Nafziger AN, Bertino JS Jr, Goss-Bley AI, Kashuba ADM. Incidence of sexual dysfunction in healthy volunteers on fluvoxamine therapy. Mar 187–190; Correction, May 341
Nafziger AN, Bertino JS Jr, Goss-Bley AI, Kashuba ADM. Reply to Banov MD: Improved outcome in fluvoxamine-treated patients with SSRI-induced sexual dysfunction [letter]. Dec 867–868
Nahas Z, Bohning DE, Molloy M, Oustz JA, Risch SC, George MS. Safety and feasibility of repetitive transcranial magnetic stimulation in the treatment of anxious depression in pregnancy: a case report. Jan 50–52
Najarian DM see Osser DN
Nakagawa A see Bachofen M
Namkoong K, Farren CK, O'Conner PG, O'Malley SS. Measurement of compliance with naltrexone in the treatment of alcohol dependence: research and clinical implications. July 449–453
Napolitano J see Katz IR
Naranjo CA see Mittmann N
Narendran R see Zarate CA Jr
Nash JL. Review of Moore BE, Fine BD (eds): *Psychoanalysis: The Major Concepts.* Feb 126–127
Nebes RD, Pollock BG, Mulsant BH, Butters MA, Zmuda MD, Reynolds CF III. Cognitive effects of paroxetine in older depressed patients. Suppl 20, 26–29
Nebes RD see Mulsant BH
Nelson EB see McElroy SL
Nelson JC see Crismon ML; Ostroff RB
Nemeroff CB, Schatzberg AF. Introduction: the phenomenology and treatment of aggression across psychiatric illnesses. Suppl 15, 3–4
Neumann PJ. Methods of cost-effectiveness analysis in the evaluation of new antipsychotics: implications for schizophrenia treatment. Suppl 3, 9–14
Neumeister A see Praschak-Rieder N
Nichol MB see McCombs JS
Nielsen AS, Mors O. Choreiform dyskinesia with acute onset and protracted course following fluoxetine treatment [letter]. Dec 868–869
Nielsen D see Roy A
Nierenberg AA, Keefe BR, Leslie VC, Alpert JE, Pava JA, Worthington JJ III, Rosenbaum JF, Fava M. Residual symptoms in depressed patients who respond acutely to fluoxetine. Apr 221–225
Nierenberg AA, Wright EC. Evolution of remission as the new standard in the treatment of depression. Suppl 22, 7–11
Nierenberg AA see Crismon ML; Sonawalla SB
Nilsson A. Lithium therapy and suicide risk. Suppl 2, 85–88
Ninan PT. Functional anatomy, neurochemistry, and pharmacology of anxiety. Suppl 22, 12–17
Ninan PT see Schulz SC
Ninomiya H see Matsuo S-I
Niskanen L see Tupala E
Noordsy DL, O'Keefe C. Effectiveness of combining atypical antipsychotics and psychosocial rehabilitation in a community mental health center setting. Suppl 19, 47–53
Nopoulos P see Ho B-C
Normann C see Grunze H
Norquist GS see Magruder KM
Nousari HC see Kimyai-Asadi A
Noviasky J see Greene YM
Nowell PD, Reynolds CF III, Buysse DJ, Dew MA, Kupfer DJ. Paroxetine in the treatment of primary insomnia: preliminary clinical and electroencephalogram sleep data. Feb 89–95
Noyes R Jr. Review of Rosenbaum JF, Pollack MH (eds): *Panic Disorder and Its Treatment.* May 343–344

Nurcombe B. Review of Campbell TW: *Smoke and Mirrors: The Devastating Effect of False Sexual Abuse Claims.* Dec 871–872
Nurnberg HG, Hensley PL, Lauriello J, Keith SJ, Parker LM. Reply to Pies R: Safety of sildenafil for antidepressant-related sexual dysfunction [letter]. Nov 792
Nurnberg HG, Lauriello J, Hensley PL, Parker LM, Keith SJ. Sildenafil for iatrogenic serotonergic antidepressant medication–induced sexual dysfunction in 4 patients. Jan 33–35
Nurnberg HG, Thompson PM, Hensley PL. Antidepressant medication change in a clinical treatment setting: a comparison of the effectiveness of selective serotonin reuptake inhibitors. Sept 574–579
Nutt DJ. Care of depressed patients with anxiety symptoms. Suppl 17, 23–27
Nutt DJ see Ballenger JC
Oakman JM see Van Ameringen M
O'Conner PG see Namkoong K
Odbert CL see Schulz SC
Ohayon MM, Guilleminault C, Priest RG. Night terrors, sleepwalking, and confusional arousals in the general population: their frequency and relationship to other sleep and mental disorders [CME]. Apr 268–276
Öhman R, Hägg S, Carleborg L, Spigset O. Excretion of paroxetine into breast milk. Aug 519–523
O'Keefe C see Noordsy DL
Ollendorf D see Mahmoud R
O'Malley SS see Namkoong K
Ombaba JM see McElroy SL
Oosthuizen PP see Emsley RA
Oquendo M see Mann JJ
O'Reardon JP see Evans DL
Osser DN, Najarian DM, Dufresne RL. Olanzapine increases weight and serum triglyceride levels. Nov 767–770
Oster G see Mahmoud R
Ostroff RB, Nelson JC. Risperidone augmentation of selective serotonin reuptake inhibitors in major depression. Apr 256–259
O'Sullivan RL see Wilhelm S
Otto MW. Cognitive-behavioral therapy for social anxiety disorder: model, methods, and outcome. Suppl 9, 14–19
Oustz JA see Nahas Z
Overø K see Feighner JP
Pallanti S, Quercioli L, Rossi A, Pazzagli A. Emergence of social phobia during clozapine treatment and its response to fluoxetine augmentation. Dec 819–823
Palmer A see Chengappa KR
Palmer DD, Henter ID, Wyatt RJ. Do antipsychotic medications decrease the risk of suicide in patients with schizophrenia? Suppl 2, 100–103
Panikkar GP, Gilman SM. Valproate-induced hyperammonemia in the psychiatric setting: 2 cases [letter]. Aug 557–559
Pardo M see Howanitz E
Parepally H see Chengappa KNR
Park J-M see Bachofen M
Parkin JR see Bachofen M
Pashdag J see Wirshing DA
Pataki C see Strober M
Paton C. Venlafaxine versus fluoxetine [letter]. Oct 708
Patten CA, Rummans TA, Croghan IT, Hurt RD, Hays JT. Development of depression during placebo-controlled trials of bupropion for smoking cessation: case reports. July 436–441
Paulsen JS see Evans JD
Pava JA see Nierenberg AA
Pazzagli A see Pallanti S
Peindl KS see Wisner KL
Perkins DO. Adherence to antipsychotic medications. Suppl 21, 25–30
Perna G, Bussi R, Allevi L, Bellodi L. Sensitivity to 35% carbon dioxide in patients with generalized anxiety disorder. June 379–384
Peters C see El-Mallakh RS
Petitto JM see Evans DL
Petti TA. Review of Silver LB: *Attention-Deficit/Hyperactivity Disorder: A Clinical Guide to Diagnosis and Treatment for Health and Mental Health Professionals, 2nd ed.* Dec 872
Petty F see Bauer MS
Peuskens J. Evolving definition of treatment resistance. Suppl 12, 4–8
Phillips SL, Heads TC, Taylor PJ, Hill GM. Sexual offending and antisocial sexual behavior among patients with schizophrenia. Mar 170–175
Pickering A see Bulik CM
Pies R. Defining psychosis in PTSD [letter with reply]. Aug 555
Pies R. Safety of sildenafil for antidepressant-related sexual dysfunction [letter with reply]. Nov 792
Pigott TA. Gender differences in the epidemiology and treatment of anxiety disorders. Suppl 18, 4–15
Pigott TA, Seay SM. Review of the efficacy of selective serotonin reuptake inhibitors in obsessive-compulsive disorder. Feb 101–106
Pigott TA see Crismon ML; Rush AJ
Pilkonis PA see Mammen OK
Pinder RM see Keller MB
Podgorski CA see Tariot PN
Pollack MH. Introduction. New frontiers in the management of social anxiety disorder: diagnosis, treatment, and clinical course. Suppl 9, 3
Pollack MH. Social anxiety disorder: designing a pharmacologic treatment strategy. Suppl 9, 20–26
Pollock BG. Adverse reactions of antidepressants in elderly patients. Suppl 20, 4–8
Pollock BG. Introduction: treatment of depression in long-term care patients. Suppl 20, 3
Pollock BG see DeVane CL; Mulsant BH; Nebes RD; Walters G
Polster DS, Wisner KL. ECT-induced premature labor: a case report [letter]. Jan 53–54
Portera L see Goldberg JF
Post RM see Goldstein TR
Postolache TT, Rosenthal RN, Hellerstein DJ, Aromin R, Kelton GM, Muran JC, Londono JH. Early augmentation of sertraline with methylphenidate [letter]. Feb 123–124
Potenza MN see Weiss EL
Powell BJ see Bauer MS
Praschak-Rieder N, Willeit M, Neumeister A, Kasper S. Reply to Rich CL: Relationship between antidepressant treatment and suicide [letter]. May 340
Preda A, Fazeli A, McKay BG, Bowers MB Jr, Mazure CM. Lamotrigine as prophylaxis against steroid-induced mania [letter]. Oct 708–709
Price LH see Carpenter LL
Priest RG see Ohayon MM
Prudic J, Sackeim HA. Electroconvulsive therapy and suicide risk. Suppl 2, 104–110
Puig A see Goodnick PJ
Quercioli L see Pallanti S
Quintero CV, Kuperman S. Review of Pruitt DB (ed): *Your Child—What Every Parent Needs to Know: What's Normal, What's Not, and When to Seek Help.* July 489
Quitkin FM see Zajecka J
Rabkin JG see Ferrando SJ
Rabkin R see Ferrando SJ
Racy JC. Review of Lazarus JA, Sharfstein SS (eds): *New Roles for Psychiatrists in Organized Systems of Care.* Jan 58
Rago WV see Rush AJ
Rao U see Strober M
Rapport DJ see Calabrese JR
Raskind MA. Evaluation and management of aggressive behavior in the elderly demented patient. Suppl 15, 45–49
Raskind MA, Cyrus PA, Ruzicka BB, Gulanski BI, for the Metrifonate Study Group. Effects of metrifonate on the cognitive, behavioral, and functional performance of Alzheimer's disease patients. May 318–325
Rasmussen SA see Carpenter LL; Eisen JL
Ravindran A see Silverstone PH
Reid WH. New vs. old antipsychotics: the Texas experience. Suppl 1, 23–25
Reimherr FW see Zajecka J
Remington G, Kapur S. D_2 and 5-HT_2 receptor effects of antipsychotics: bridging basic and clinical findings using PET. Suppl 10, 15–19
Remington G see Chong S-A
Revicki DA. Pharmacoeconomic evaluation of treatments for refractory schizophrenia: clozapine-related studies. Suppl 1, 7–11
Reynolds CF III see Mulsant BH; Nebes RD; Nowell PD; Walters G
Reznik I, Benatov R, Sirota P. Long-term efficacy and tolerability of quetiapine in treatment-refractory schizophrenia: a case study. Suppl 23, 16
Ricca V see Faravelli C
Rice DP. Economic impact of schizophrenia. Suppl 1, 4–6
Rich CL. Relationship between antidepressant treatment and suicide [letter with reply]. May 340
Richelson E. Receptor pharmacology of neuroleptics: relation to clinical effects. Suppl 10, 5–14
Rigali J see Strober M
Ringman JM, Cummings JL. Metrifonate: update on a new antidementia agent. Nov 776–782
Ringold A see Chatterjee CR
Rink J see Stein DJ
Risby ED. Review of Lam R (ed): *Seasonal Affective Disorder and Beyond: Light Treatment for SAD and Non-SAD Conditions.* June 411
Risch SC see Nahas Z
Risperidone Study Group see Katz IR
Roberts MC see Emsley RA
Robinson D see Schulz SC
Roca CA, Schmidt PJ, Rubinow DR. A follow-up study of premenstrual syndrome. Nov 763–766
Rogers T see Bork JA
Rojas VM, Davies RK. Reserpine treatment of comorbid Tourette's disorder and tardive dystonia [letter]. Oct 709–710

Ronchi O see Faravelli C
Roose SP. Tolerability and patient compliance. Suppl 17, 14–17
Roose SP, Spatz E. Treatment of depression in patients with heart disease. Suppl 20, 34–37
Rosebush PI see Garside S
Rosenbaum JF see Fava M; Moroz G; Nierenberg AA; Sonawalla SB; Zajecka J
Rosenberg R see Asnis GM
Rosenthal J see Hellerstein DJ
Rosenthal RN see Postolache TT
Rossi A see Pallanti S
Roth-Schechter B see Asnis GM
Rothschild AJ, Bates KS, Boehringer KL, Syed A. Olanzapine response in psychotic depression. Feb 116–118
Rothschild AJ, Byrne SE. Reply to El-Mallakh RS: Can long-term antidepressant use be depressogenic? [letter] Apr 263–264
Rowan A see Weller EB
Roy A, Nielsen D, Rylander G, Sarchiapone M, Segal N. Genetics of suicide in depression. Suppl 2, 12–17
Roy-Byrne PP, Stein MB, Russo J, Mercier E, Thomas R, McQuaid J, Katon WJ, Craske MG, Bystrisky A, Sherbourne CD. Panic disorder in the primary care setting: comorbidity, disability, service utilization, and treatment. July 492–499
Roy-Byrne PP see Comtois KA; Elliott AJ
Rubinow DR see Roca CA
Rudd GD see Calabrese JR
Rudolph RL. Introduction. Goal of antidepressant therapy: response or remission and recovery? Suppl 6, 3–4
Ruiz P. Review of Alarcón RD, Foulks EF, Vakkur M (eds): *Personality Disorder and Culture: Clinical and Conceptual Interactions.* Mar 197
Rummans TA see Patten CA
Rush AJ. Strategies and tactics in the management of maintenance treatment for depressed patients. Suppl 14, 21–26
Rush AJ, Rago WV, Crismon ML, Toprac MG, Shon SP, Suppes T, Miller AL, Trivedi MH, Swann AC, Biggs MM, Shores-Wilson K, Kashner TM, Pigott T, Chiles JA. Medication treatment for the severely and persistently mentally ill: the Texas Medication Algorithm Project. May 284–291
Rush AJ see Crismon ML; Miller ML; Schulberg HC; Shon SP
Russe J see Roy-Byrne PP
Russell JM see Hirschfeld RMA
Russo J see Elliott A
Ruther E see Elie R
Ruzicka BB see Raskind MA
Rylander G see Roy A
Sachs GS, Gaughan S. Clinical practice guidelines: praise and problems [editorial]. Jan 7–8
Sachs GS, Guille C. Weight gain associated with use of psychotropic medications. Suppl 21, 16–19
Sachs GS see Calabrese JR
Sackeim HA see Crismon ML; Prudic J
Sajatovic M see Bauer MS
Salinas E see Elie R
Salis P see Tondo L
Salomon RM. Review of Brown TM, Stoudemire A: *Psychiatric Side Effects of Prescription and Over-the-Counter Medications: Recognition and Management.* Jan 58–59
Salomon RM. Review of Pincus HA, Lieberman JA, Ferris S (eds): *Ethics in Psychiatric Research: A Resource Manual for Human Subjects Protection.* Aug 560–561
Salzman C. Practical considerations for the treatment of depression in elderly and very elderly long-term care patients. Suppl 20, 30–33
Sanderson W see Asnis J
Sarchiapone M see Roy A
Sasaki Y see Matsuo S-I
Sasson Y, Zohar J, Gross R, Taub M, Fux M. Response to missile attacks on civilian targets in patients with panic disorder. June 385–388
Saxena S. Reply to Mahendran R: Obsessive-compulsive symptoms with risperidone [letter]. Apr 262–263
Scamonatti L see Tondo L
Schaefer V see Bauer MS
Scharf MB see Asnis GM
Schatzberg AF. Antidepressant effectiveness in severe depression and melancholia. Suppl 4, 14–21
Schatzberg AF, DeBattista C. Phenomenology and treatment of agitation. Suppl 15, 17–20
Schatzberg AF see Nemeroff CB
Scheifler PL see McEvoy JP
Schlosser S see Black DW
Schlozman SC. Reply to Brenner I: Upper-extremity self-amputation in a case of dissociative identity disorder [letter]. Oct 705–706
Schmahl CG see Bohus MJ
Schmidt PJ see Roca CA
Schmidt-Lackner S see Strober M
Schneider LS. Pharmacologic management of psychosis in dementia. Suppl 8, 54–60
Schooler NR see Chengappa KR
Schulberg HC, Katon WJ, Simon GE, Rush AJ. Best clinical practice: guidelines for managing major depression in primary medical care. Suppl 7, 19–26
Schulberg HC see Ballenger JC
Schulz SC, Thompson PA, Jacobs M, Ninan PT, Robinson D, Weiden PJ, Yadalam K, Glick ID, Odbert CL. Lithium augmentation fails to reduce symptoms in poorly responsive schizophrenic outpatients. June 366–372
Schuster P see Wittchen H-U
Seay SM see Pigott TA
Sederer M see Zarate CA Jr
Segal N see Roy A
Sekine Y see Iyo M
Seroquel Trial 48 Study Group see McManus DQ
Shaffer D, Craft L. Methods of adolescent suicide prevention. Suppl 2, 70–74
Shaw M, Brown R. Quetiapine in the psychosocial rehabilitation of a patient with chronic schizophrenia. Suppl 23, 17–19
Shear MK see Mammen OK
Shear NH see Mittmann N
Sheehan DV. Current concepts in the treatment of panic disorder. Suppl 18, 16–21
Sheehan DV. Introduction. New treatments for anxiety disorders: clinical approaches for successful outcomes. Suppl 18, 3
Sheehan DV. Venlafaxine extended release (XR) in the treatment of generalized anxiety disorder. Suppl 22, 23–28
Sheeley WF. Capitation [letter with reply]. Jan 54
Shelton RC. Mood-stabilizing drugs in depression. Suppl 5, 37–40
Shelton RC. Review of Briley M, Montgomery S (eds): *Antidepressant Therapy at the Dawn of the Third Millennium.* Oct 711–712
Shelton RC. Review of Clark DM, Fairburn CG (eds): *Science and the Practice of Cognitive Behaviour Therapy.* May 343
Shelton RC. Treatment options for refractory depression. Suppl 4, 57–61
Sherbourne CD see Roy-Byrne PP
Sheth S see Chengappa KR
Shi J see McCombs JS
Shon SP, Crismon ML, Toprac MG, Trivedi M, Miller AL, Suppes T, Rush AJ. Mental health care from the public perspective: the Texas Medication Algorithm Project. Suppl 3, 16–20
Shon SP see Miller AL; Rush AJ
Shores-Wilson K see Rush AJ
Shulman KI, Walker SE. Refining the MAOI diet: tyramine content of pizzas and soy products. Mar 191–193
Shulman KI see Mittmann N
Silver IL see Mittmann N
Silverman JJ. Review of Katschnig H, Freeman H, Sartorius N (eds): *Quality of Life in Mental Disorders.* July 489–490
Silverstone PH, Ravindran A. Reply to Judge R: Once-daily venlafaxine XR compared with fluoxetine in outpatients with depression and anxiety [letter]. Nov 796
Silverstone PH, Ravindran A, for the Venlafaxine XR 360 Study Group. Once-daily venlafaxine extended release (XR) compared with fluoxetine in outpatients with depression and anxiety. Jan 22–28
Simeon D see Stein DJ
Simon GE see Schulberg HC
Simpson HB, Gorfinkle KS, Liebowitz MR. Cognitive-behavioral therapy as an adjunct to serotonin reuptake inhibitors in obsessive-compulsive disorder: an open trial. Sept 584–590
Simpson SG, Jamison KR. Risk of suicide in patients with bipolar disorders. Suppl 2, 53–56
Sirota P see Reznik I
Sisitsky T see Greenberg PE
Smelson DA see Howanitz E
Smeraldi E see Franchini L
Smith MW see Swartz JR
Smith RR see McCombs JS
Smith-Jackson E see Goldstein TR
Sobel M, Jaggers ED, Franz MA. New-onset diabetes mellitus associated with the initiation of quetiapine treatment [letter]. Aug 556–557
Solomon J see Lejoyeux M
Sonawalla SB, Spillman MK, Kolsky AR, Alpert JE, Nierenberg AA, Rosenbaum JF, Fava M. Efficacy of fluvoxamine in the treatment of major depression with comorbid anxiety disorders. Sept 580–583
Soutullo CA see McElroy SL
Spatz E see Roose SP
Sperner-Unterweger B see Kurzthaler I
Spigset O see Öhman R
Spillman MK see Sonawalla SB
Spinhoven P see Bakker A
Staab JP see Evans DL
Stack J see Mulsant BH
Stahl SM. Antidepressants: the Blue-Chip psychotropic for the modern treatment of anxiety disorders [BRAINSTORMS]. June 356–357
Stahl SM. Antipsychotic polypharmacy, part 1: therapeutic option or dirty little secret? [BRAINSTORMS] July 425–426

Stahl SM. Antipsychotic polypharmacy, part 2: tips on use and misuse [BRAINSTORMS]. Aug 506–507
Stahl SM. Introduction: what makes an antipsychotic atypical? Suppl 10, 3–4
Stahl SM. Mergers and acquisitions among psychotropics: antidepressant takeover of anxiety may now be complete [BRAINSTORMS]. May 282–283
Stahl SM. Molecular neurobiology for practicing psychiatrists, part 1: overview of gene activation by neurotransmitters [BRAINSTORMS]. Sept 572–573
Stahl SM. Molecular neurobiology for practicing psychiatrists, part 2: how neurotransmitters activate second messenger systems [BRAINSTORMS]. Oct 647–648
Stahl SM. Molecular neurobiology for practicing psychiatrists, part 3: how second messengers "turn on" genes by activating protein kinases and transcription factors [BRAINSTORMS]. Nov 731–732
Stahl SM. Molecular neurobiology for practicing psychiatrists, part 4: transferring the message of chemical neurotransmission from presynaptic neurotransmitter to postsynaptic gene expression [BRAINSTORMS]. Dec 813–814
Stahl SM. Peptides and psychiatry, part 1: how synthesis of neuropeptides differs from classical neurotransmitter synthesis [BRAINSTORMS]. Jan 5–6
Stahl SM. Peptides and psychiatry, part 2: substance P and the neurokinins: novel peptide neurotransmitters in psychopharmacology [BRAINSTORMS]. Feb 77–78
Stahl SM. Peptides and psychiatry, part 3: substance P and serendipity: novel psychotropics are a possibility [BRAINSTORMS]. Mar 140–141
Stahl SM. Reply to Masand P: Relative weight gain among antipsychotics [letter]. Oct 706–708
Stahl SM. Selecting an atypical antipsychotic by combining clinical experience with guidelines from clinical trials. Suppl 10, 31–41
Stahl SM. Why settle for silver, when you can go for gold? response vs. recovery as the goal of antidepressant therapy [BRAINSTORMS]. Apr 213–214
Stassen HH see Angst J
Stein DJ, Rink J. Effects of "Ecstasy" blocked by serotonin reuptake inhibitors [letter]. July 485
Stein DJ, Simeon D. Nosology of compulsive skin-picking [letter]. Sept 618
Stein DJ see Emsley RA
Stein MB see Moutier CY; Roy-Byrne PP
Stern RG see Howanitz E
Stiglmayr CE see Bohus MJ
Stimmel GL see McCombs JS
Stip E. Quetiapine and cognitive improvement in a patient with schizophrenia. Suppl 23, 27–28
Strakowski SM see McElroy SL
Strickland RT see Carroll NB
Strober M, DeAntonio M, Schmidt-Lackner S, Pataki C, Freeman R, Rigali J, Rao U. Pharmacotherapy of depressive illness in adolescents: an open-label comparison of fluoxetine with imipramine-treated historical controls. Mar 164–169
Su K see Lane H-Y
Sullivan PF see Bulik CM
Sundell KL see Zajecka J
Suppes T see Rush AJ; Shon SP
Swann AC. Treatment of aggression in patients with bipolar disorder. Suppl 15, 25–28
Swann AC see Rush AJ
Swartz JR, Ananth J, Smith MW, Burgoyne KS, Gadasally R, Arai Y. Olanzapine treatment after clozapine-induced granulocytopenia in 3 patients. Feb 119–121
Syed A see Rothschild AJ
Szuba MP see Evans DL
Taboada I. Clinical heterogeneity between atypical antipsychotics in the treatment of schizophrenia: a case report. Suppl 23, 23–24
Takasiba T see Matsuo S-I
Takei N see Iyo M
Tamura RN see Zajecka J
Tan C-H see Chong S-A
Tandon R, Milner K, Jibson MD. Antipsychotics from theory to practice: integrating clinical and basic data. Suppl 8, 21–28
Tandon R see Maixner SM
Targum SD, Abbott JL. Psychoses in the elderly: a spectrum of disorders. Suppl 8, 4–10
Tariot PN. Introduction. Awakening psychiatry to geriatrics: Finagle, Osler, and Ginger Rogers. Suppl 8, 3
Tariot PN. Older patient: the ongoing challenge of efficacy and tolerability. Suppl 23, 29–30
Tariot PN. Treatment of agitation in dementia. Suppl 8, 11–20
Tariot PN, Jakimovich LJ, Erb R, Cox C, Lanning B, Irvine C, Podgorski CA. Withdrawal from controlled carbamazepine therapy followed by further carbamazepine treatment in patients with dementia. Oct 684–689
Tariot PN see Greene YM
Taub M see Sasson Y
Tavcar R, Dernovsek MZ, Zvan V. Self-amputation of left hand: a case report [letter]. Nov 793–794
Taylor P Jr see McElroy SL
Taylor PJ see Phillips SL
Tennen H see Lenderking WR
Terman JS see Terman M
Terman M, Terman JS. Bright light therapy: side effects and benefits across the symptom spectrum. Nov 799–808
Testa MA see Lenderking WR
Texas Consensus Conference Panel on Medication Treatment of Major Depressive Disorder see Crismon ML
Thase ME. Antidepressant treatment of the depressed patient with insomnia. Suppl 17, 28–31
Thase ME. How should efficacy be evaluated in randomized clinical trials of treatments for depression? Suppl 4, 23–31
Thase ME. Introduction: defining remission in patients treated with antidepressants. Suppl 22, 3–6
Thase ME. Long-term nature of depression. Suppl 14, 3–9
Thase ME. Redefining antidepressant efficacy toward long-term recovery. Suppl 6, 15–19
Thase ME. Summary: defining remission in patients treated with antidepressants. Suppl 22, 35–36
Thase ME see Crismon ML; Mammen OK
Thienhaus OJ. Review of Salzman C (ed): *Clinical Geriatric Psychopharmacology, 3rd ed.* Oct 711
Thomas R see Roy-Byrne PP
Thompson C. Mirtazapine versus selective serotonin reuptake inhibitors. Suppl 17, 18–22
Thompson PA see Schulz SC
Thompson PM see Nurnberg HG
Tiihonen J see Tupala E
Tohen M, Grundy S. Management of acute mania. Suppl 5, 31–34
Tohen M see Zarate CA Jr
Tollefson GD, Andersen SW. Should we consider mood disturbance in schizophrenia as an important determinant of quality of life? Suppl 5, 23–29
Tomassini EC see Zarate CA Jr
Tondo L, Baldessarini RJ, Hennen J, Minnai GP, Salis P, Scamonatti L, Masia M, Ghiani C, Mannu P. Suicide attempts in major affective disorder patients with comorbid substance use disorders. Suppl 2, 63–69
Tondo L see Baldessarini RJ
Toprac MG see Rush AJ; Shon SP
Trawöger R see Deisenhammer EA
Trivedi MH see Crismon ML; Rush AJ; Shon SP
Tsai S-J see Hwang J-P
Tseng Y-T see Lane H-Y
Tsukamoto T see Iyo M
Tunis SL, Johnstone BM, Gibson PJ, Loosbrock DL, Dulisse BK. Changes in perceived health and functioning as a cost-effectiveness measure for olanzapine versus haloperidol treatment of schizophrenia. Suppl 19, 38–46
Tupala E, Niskanen L, Tiihonen J. Transient syncope and ECG-changes associated with the concurrent administration of clozapine and diazepam [letter]. Sept 619–620
Turner RR see Lenderking WR
Tylee A. Depression in the community: physician and patient perspective. Suppl 7, 12–16
Tylee A see Ballenger JC
Uldall KK see Elliott AJ
Underwood MD see Mann JJ
Vakoch DA. Review of Markowitz JC: *Interpersonal Psychotherapy for Dysthymic Disorder.* Sept 621
Van Ameringen M, Mancini C, Oakman JM. Nefazodone in social phobia. Feb 96–100
van Balkom AJLM see Bakker A
van Dyck R see Bakker A
Velligan DI, Miller AL. Cognitive dysfunction in schizophrenia and its importance to outcome: the place of atypical antipsychotics in treatment. Suppl 23, 25–26
Venlafaxine XR 360 Study Group see Silverstone PH
Versiani M, Mehilane L, Gaszner P, Arnaud-Castiglioni R. Reboxetine, a unique selective NRI, prevents relapse and recurrence in long-term treatment of major depressive disorder. June 400–406
Volavka J. Effects of clozapine on aggression and substance abuse in schizophrenic patients. Suppl 12, 43–46
Voruganti LP see Awad AG
Wagner BE see Judge R
Walden J see Grunze H
Walker SE see Shulman KI
Walsh JK see Asnis GM
Walters G, Reynolds CF III, Mulsant BH, Pollock BG. Continuation and maintenance pharmacotherapy in geriatric depression: an open-trial comparison of paroxetine and nortriptyline in patients older than 70 years. Suppl 20, 21–25
Waltrip C see El-Mallakh RS
Ward HE see Evans DL
Ware MR see Emmanuel NP
Warshaw MG see Eisen JL

Wechdorn H see Kurzthaler I
Wedlund PJ see Bork JA
Weiden PJ see Allison DB; Aquila R; Schulz SC
Weinstein D. Review of McCance-Katz EF, Kosten TR (eds): *New Treatments for Chemical Addictions (Review of Psychiatry Series, Vol. 17).* Aug 561
Weinstock LS. Gender differences in the presentation and management of social anxiety disorder. Suppl 9, 9–13
Weisburd DE. What about the patient? Suppl 3, 38–41
Weiss EL, Potenza MN, McDougle CJ, Epperson CN. Olanzapine addition in obsessive-compulsive disorder refractory to selective serotonin reuptake inhibitors: an open-label case series. Aug 524–527
Weller EB, Rowan A, Elia J, Weller RA. Aggressive behavior in patients with attention-deficit/hyperactivity disorder, conduct disorder, and pervasive developmental disorders. Suppl 15, 5–11
Weller RA see Weller EB
Wenzel KW see Bachofen M
Westenberg HGM. Pharmacology of antidepressants: selectivity or multiplicity? Suppl 17, 4–8
Wilhelm S, Keuthen NJ, Deckersbach T, Engelhard IM, Forker AE, Baer L, O'Sullivan RL, Jenike MA. Self-injurious skin picking: clinical characteristics and comorbidity. July 454–459
Willeit M see Praschak-Rieder N
Wilson JW see Coley KC
Wingate B see Evans DL
Winsberg ME, Cassic KS, Koran LM. Hoarding in obsessive-compulsive disorder: a report of 20 cases. Sept 591–597
Wirshing DA, Wirshing WC, Kysar L, Berisford MA, Goldstein D, Pashdag J, Mintz J, Marder SR. Novel antipsychotics: comparison of weight gain liabilities. June 358–363
Wirshing WC see Wirshing DA
Wisner KL, Cott A. Isotretinoin treatment of a woman with bipolar disorder [letter]. June 407–408
Wisner KL, Peindl KS, Gigliotti T, Hanusa BH. Obsessions and compulsions in women with postpartum depression. Mar 176–180
Wisner KL see Polster DS
Wittchen H-U, Lieb R, Wunderlich U, Schuster P. Comorbidity in primary care: presentation and consequences. Suppl 7, 29–36
Wittchen H-U see Ballenger JC
Wittlin B see Bauer MS
Worthington JJ III see Nierenberg AA
Wright EC see Nierenberg AA
Wunderlich U see Wittchen H-U
Wyatt RJ see Palmer DD
Yadalam K see Schulz SC
Yang C-H see Hwang J-P
Yehuda R. Managing anger and aggression in patients with posttraumatic stress disorder. Suppl 15, 33–37
Yiğit S see Çetin M
Yorston G. Half century of psychosis: a case report describing the ethical dilemma of treating an elderly patient with long-term schizophrenia. Suppl 23, 31–33
Young A see Macmillan I
Young AH. Reply to Haddad P: Pharmacists lack knowledge of antidepressant discontinuation symptoms [letter]. Feb 125
Zajecka J, Amsterdam JD, Quitkin FM, Reimherr FW, Rosenbaum JF, Tamura RN, Sundell KL, Michelson D, Beasley CM Jr. Changes in adverse events reported by patients during 6 months of fluoxetine therapy. June 389–394
Zaleplon Clinical Study Group see Elie R
Zanardi R see Franchini L
Zarate CA Jr, Tohen M, Narendran R, Tomassini EC, McDonald J, Sederer M, Madrid AR. Adverse effect profile and efficacy of divalproex sodium compared with valproic acid: a pharmacoepidemiology study. Apr 232–236
Zimmerman M, Mattia JI. Psychotic subtyping of major depressive disorder and posttraumatic stress disorder. May 311–314
Zimmerman M, Mattia JI. Reliability and validity of a screening questionnaire for 13 DSM-IV Axis I disorders (the Psychiatric Diagnostic Screening Questionnaire) in psychiatric outpatients. Oct 677–683
Zohar J see Sasson Y
Zmuda MD see Nebes RD
Zvan V see Tavcar R